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Abstract 
As an increasingly prevalent chronic disease, diabetes represents one of the 
fastest growing health burdens to both the developed and developing world.  In an 
effort to improve the management and treatment of diabetes, implantable sensors that 
continuously monitor glucose levels have become popular alternatives to patient-
administered finger prick measurements of blood glucose.  However, following 
implantation, the performance of these implants suffers from inaccurate and erratic 
readings that compromise their useful lives.  As a result, implantable glucose sensors 
remain limited as a platform for the reliable management of diabetes.  While the 
interaction between the sensor and its surrounding tissue has been posited as a culprit 
for erroneous in vivo sensor performance, there remains little evidence to support that 
theory. 
This dissertation describes the effects that implant-associated tissue reactions 
have on implantable sensor function.  Since tissue response to an implant changes over 
time, the overall effect of these tissue reactions is broken into two temporal phases: (1) 
the phase of weeks to months following implantation when a mature foreign body 
capsule is present around the sensor and (2) the phase of days to weeks immediately 
following sensor implantation when a provisional matrix of proteins and inflammatory 
cells envelops the sensor. 
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Late stage sensor responses to implantation are marked by both an attenuated 
sensor signal and a significant time lag relative to blood glucose readings.  For this later 
stage of sensor response, a computational model of glucose transport through the 
interstitial space and foreign body capsule was derived and implemented.  Utilizing 
physiologically relevant parameters, the model was used to mechanistically study how 
each constituent part of the capsular tissue could affect sensor response with respect to 
signal attenuation and lag.  Each parameter was then analyzed using logarithmic 
sensitivity analysis to study the effects of different transport variables on both lag and 
attenuation.  Results identified capsule thickness as the strongest determinant of sensor 
time lag, while subcutaneous vessel density and capsule porosity had the largest effects 
on attenuation of the sensor signal. 
For the phase of early stage tissue response, human whole blood was used as a 
simple ex vivo experimental system.  The impacts of protein accumulation at the sensor 
surface (biofouling effects) and cellular consumption of glucose in both the biofouling 
layer and in the bulk (metabolic effects) on sensor response were assessed.  Medtronic 
Minimed SofSensor glucose sensors were incubated in whole blood, plasma diluted 
whole blood, and cell-free platelet poor plasma (PPP) to analyze the effects of different 
blood constituents on sensor function.  Experimental conditions were then simulated 
using MATLAB to predict the relative impacts of biofouling and metabolic effects on the 
observed sensor responses.  It was found that the physical barrier to glucose transport 
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presented by protein biofouling did not hinder glucose movement to the sensor surface.  
Instead, glucose consumption by inflammatory cells was identified as the major culprit 
for generating poor sensor performance immediately following implantation. 
Lastly, a novel, biomimetic construct was designed to mimic the in vivo 3D 
cellular setting around the sensor for the focused in vitro investigation of early stage 
effects of implantation on glucose sensor performance.  Results with this construct 
demonstrate similar trends in sensor signal decline to the ex vivo cases described above, 
suggesting this construct could be used as an in vitro platform for assessing implantable 
glucose sensor performance. 
In total, it may be concluded from this dissertation that instead of sensors 
“failing” in vivo, as is often reported, that different physiological factors mediate long 
term sensor function by altering the environment around the implant.  For times 
immediately following implantation, sensor signals are mediated by the presence of 
inflammatory macrophages adhered on the surface.  However, at longer times post-
implantation, sensor signals are mediated not by the consumptive capacity of 
macrophages, but instead by the subcutaneous vessel density surrounding the sensor as 
well as the porosity and thickness of the foreign body capsule itself.  Taken in concert, 
the results of this dissertation provide a temporal framework for outlining the effects of 
tissue response on sensor performance, hopefully informing more biocompatible 
glucose sensor designs in the future.
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Chapter 1. Research Objectives 
1.1 Significance of Research 
There has been a significant thrust in the diabetes management community to 
create a viable, long term, continuously measuring glucose sensor to improve patient 
point of care.  In order to achieve these continuous measurements, the majority of 
designs have revolved around implantable platforms.  However, both the 
biocompatibility of these implants and the subsequent tissue effects on sensor 
performance have not been well characterized.  While it has been accepted in the 
parlance of the diabetes community to state that sensors fail when implanted, a growing 
body of research suggests that instead of sensors actually failing, that tissue interactions 
with the indwelling sensor may inhibit local sensing capabilities.  This dissertation will 
address the modes with which tissue reactions to implantation affect sensor response.  
Specifically, we will examine two different scenarios: (1) the effect of a mature foreign 
body capsule surrounding the sensor (late stage tissue response) and (2) the effect of 
early stages of implant-associated inflammation upon sensor function (early stage tissue 
response). 
Both stages are of interest in improving long term sensor viability within the 
body.  An increased awareness of long term tissue effects on sensor functionality will 
inform more rational surface designs for combating foreign body encapsulation.  
Similarly, as the useful clinical life of these sensors is frequently less than one week 
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when implanted, it is instructive to assess what early stage biological processes within 
that time window are affecting the local milieu, thereby limiting sensor capability in 
vivo.  Because each stage has a different geometry and biological components, they are 
considered separately in how they impact sensor response.  
To assess how these early and late stage tissue responses will affect the local 
sensing environment, we will examine the interaction between the sensor and 
implantation tissue through both computational and experimental models, ultimately 
presenting an in vitro construct for assessing sensor biocompatibility for improved in 
vivo performance.  The specific aims of this dissertation are as follows: 
1.2 Specific Aims 
1.2.1 Specific Aim 1: Numerical Characterization of the Influences of 
Late Stage, Fully Formed Capsular Tissue on Implanted Glucose 
Sensor Function 
As the long term tissue effects to sensor implantation have a stable number of 
components and geometry, they can be numerically modeled.  A computational 
transport model of diffusion of glucose out of surrounding capillaries and through fully 
formed capsular tissue will be constructed to assess which aspects of the tissue 
contribute most to a depleted sensor response and increased time lag.  Physiologically 
relevant values of capsule diffusion coefficient, capsule porosity, cellular glucose 
consumption, capsule thickness and subcutaneous vessel density will be used as inputs 
to create simulated sensor traces that mimic experimental instances of time lag and 
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signal attenuation for a given blood glucose profile.  Once the model is constructed and 
validated, it will be run for a range of values for each of the above parameters, and using 
logarithmic sensitivity analysis, the relative contributions of each parameter in affecting 
sensor lag and attenuation will be calculated.  With this model, it is hypothesized that 
decreased long term sensor response as manifest through increases in lag time and 
signal attenuation are promoted by the effects of inflammation/wound healing vis-à-vis 
the formation of a foreign body capsule. 
1.2.2 Specific Aim 2: Characterization of the Early Stage Effects of 
Implantation on Glucose Sensor Performance 
The environment immediately surrounding an implanted sensor contains both 
fouling protein layers as well as metabolically active inflammatory cell types like 
neutrophils and macrophages, all of which have been purported as potential culprits in 
affecting acute sensor response.  Using commercially available Medtronic Minimed 
SofSensor implantable glucose sensors, we will recreate early tissue/sensor interactions 
in vitro by incubating sensors in whole blood as well as different constituents of whole 
blood, such as platelet poor plasma.  Reported sensor trends will be corroborated by 
secondary blood glucose measurements to offer concrete observations of how glucose 
concentrations change during the period of sensor incubation.  Additionally, a 
computational model of glucose transport through initial inflammatory tissue will 
present further evidence of how these early tissue responses will affect sensor 
performance.  It is hypothesized that the presence of blood constituents such as 
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inflammatory macrophages proximal to the sensor surface create a depleted 
environment for glucose sensing via the consumption of glucose, rendering the 
detection ability of the glucose oxidase enzyme useless. 
1.2.3 Specific Aim 3: Development of a Novel Biomimetic Construct of 
the In Vivo 3D Cellular Setting around the Sensor for the Focused In 
Vitro Investigation of Early Stage Effects of Implantation on Glucose 
Sensor Performance 
To further investigate the role that the presence of adhered inflammatory 
macrophages on the sensor surface has on sensor function soon after implantation, we 
propose the construction of a novel biomimetic construct that accurately recapitulates 
the in vivo 3D protein and cellular milieu around the sensor.  To make this construct as 
physiologically relevant as possible, it will be comprised of fibrin, which is the primary 
component of the protein biofouling layer that adsorbs to implanted sensors in vivo.  
Macrophages will be embedded into the gel at a concentration similar to concentrations 
observed around implants in vivo.  These constructs will then be subsequently wrapped 
around otherwise functioning sensors to analyze the effects of adhered inflammatory 
cell presence on sensor performance.  To ensure that any decrease in signal is a function 
of cell-mediated uptake of glucose, sensors surrounded by macrophage-embedded gels 
will be compared against readings of both bare sensors and sensors surrounded by 
acellular gels. To examine how activation of macrophages into pro-inflammatory 
phenotypes will impact sensor output, macrophages will be stimulated with both 
lipopolysaccharide (LPS) and phorbol myristate acetate (PMA).  Experimental results of 
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sensor decline will be compared against those of a computational model of the 
experimental setup to ensure that the observed trends can be reasonable predictors of 
sensor performance.  If successful, this in vitro system could serve as a robust and useful 
method to investigate the functional effects of implantation on not only glucose sensors, 
but any implantable biosensor. 
1.3 Organization and Presentation of Dissertation 
The objective of this dissertation is to analyze the impacts of both short and long 
term tissue reactions to implantation on glucose sensor function.  Chapter 3 focuses 
exclusively on the effects that long term tissue reactions to implantation will have on 
sensor function.  Chapter 4 details an ex vivo system for evaluating the effects that short 
term tissue reaction will have on sensor function.  Building on the findings of Chapter 4, 
Chapter 5 features the design and characterization of a novel biomimetic system that can 
recapitulate the ex vivo results of the previous chapter for the assessment of glucose 
sensor performance.  Finally, Chapter 6 summarizes the current findings and suggests 
future avenues for continuing this research. 
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Chapter 2: Background 
2.1 Disease Burden of Diabetes and the Role of Implantable 
Glucose Sensors in Improved Disease Management 
According to Center for Disease Control estimates from 2011, 25.8 million 
Americans have diabetes.  Of this group, over 200,000 people die each year due to 
disease-related complications, making diabetes the seventh leading cause of death in the 
United States [1].  Those afflicted also live with an increased risk of heart disease, stroke, 
high blood pressure, blindness, kidney failure and neurological disorders [1].  
Additionally, the disease represents a significant strain on health care, as the American 
Diabetes Association estimates that indirect and direct costs due to diabetes totaled over 
$174 billion in 2007 [2]. Both at home and clinically, one method for minimizing diabetes 
related pathologies is the constant management of blood glucose changes.  The most 
traditional method for the monitoring of blood glucose levels is the “finger prick” 
technique, though reports have shown that only 30% of type 1 diabetics and 20% of type 
2 diabetics on insulin treatment check blood glucose levels more than once a day [3].   
Given both the insufficient adherence to glucose monitoring suggestions and the 
inability for the finger prick method to identify rapid hyperglycemic events, there exists 
the need for continuous glucose sensors.  Ultimately, the hope of continuous sensors is 
that they will be able to interface with external insulin pumps, thereby creating a 
feedback loop that will supply insulin in real time based upon a patient’s current blood 
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glucose levels.  Continuous invasive routes for glucose measurement have already been 
introduced to the public market by companies like Medtronic and Cygnus. 
While current invasive glucose sensor technology has shown both high 
selectivity and sensitivity, obstacles still exist in making it a viable option in a clinical 
setting.  The Food and Drug Administration (FDA) has yet to approve invasive 
technologies for longer than a week.  Medtronic’s current measurement paradigms, the 
implantable REAL-TimeTM system and the new MiniMed 530G system, have only been 
approved for three day and six day use by the FDA, respectively [4-7].  Similarly, 
sensing designs from Abbott Labs and DexCom have only been approved for five and 
seven days, respectively [6, 7].  While failure of the sensor itself may contribute to such a 
short working life, an increasing body of research has suggested that interaction 
between the implanted tissue and the sensor is the main culprit in short sensor life [8-
13].   
2.2 Tissue Response to Implanted Objects 
In order to develop a sensor that can measure analyte concentrations with high 
sensitivity for a prolonged amount of time, the interaction between the sensor and the 
surrounding tissue must be considered.  Once implanted, no sensor will exist as an inert 
object in the body since all implants will alter the surrounding environment.  However, 
minimizing the effects of the sensor on the tissue will reduce errors associated with 
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inflammation.  A more thorough account of tissue response to implanted materials is 
presented by Anderson [14]. 
When a foreign body is implanted, there will be injury to vascularized tissue.  
With this injury comes the exudation of blood borne proteins, fluid and cells to the site 
of implantation.  The convection of blood borne proteins induces an initial coagulation 
cascade where fibrin is formed from the cleavage of fibrinogen by thrombin.  This fibrin 
network will then coalesce around the implant to form a provisional matrix or 
biofouling layer.  In addition to the fibrin skeleton, the provisional matrix contains a 
number of different factors that contribute to the formation of an inflammatory 
response.  First, it contains adhesive molecules such as fibronectin and thrombospondin 
that will allow for inflammatory cell attachment and migration.  Secondly, the 
provisional matrix contains a number of cytokines and growth factors that will 
coordinate the extent and pace of immune reaction [14].  These glycoproteins establish 
chemotactic gradients within the matrix that attract inflammatory cells to the site of 
injury.  Binding of cytokines to specific cellular membrane receptors triggers second 
messenger cascades that immediately induce alterations in gene expression and 
eventually affect cellular behavior. 
Once the biofouling layer has been established, inflammatory cells, guided by 
chemotactic gradients, changes in vascular flow, and the presence of adhesion 
molecules, will begin to infiltrate the site of inflammation.  Neutrophils will initially 
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interrogate the injured tissue and attempt to phagocytose the implanted sensor.  
However, given the size of implants relative to cells, neutrophils will recruit 
macrophages to the site of injury to attempt phagocytosis.  Additionally, macrophages 
will release cytokines, chemokines and growth promoting factors to encourage the 
recruitment of even more cell types.  If neutrophils and macrophages cannot dispose of 
the foreign body, fibroblasts will migrate to the injury via the release of cytokines by 
macrophages.  Fibroblasts generate collagen and proteoglycans to deposit around the 
site of injury.  The extracellular matrix constituents produced by these cells forms the 
basis for the foreign body capsule.  This capsule will grow in both size and density as 
the chronic inflammatory process persists.  Figure 1 presents an idealized time course 
for tissue effects to sensor implantation. 
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Figure 1: Idealized time course of tissue response to implantation 
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2.3 Effects of the Foreign Body Capsule on Implanted Sensor 
Performance 
The foreign body capsule has long been considered to be a main cause for the 
short in vivo shelf life of implantable sensors [8, 12, 15].  Many have postulated different 
possible effects that the foreign body capsule would have upon sensor performance.  
Capsular tissue has been posited to decrease sensor effectiveness in many different 
ways, depending on its stage of development.  Fully developed and well defined 
capsular tissue has been thought to decrease sensor function through the presence of 
underdeveloped microvascular networks for limited glucose delivery, local analyte 
consumption by metabolically active inflammatory cells, and decreased diffusion 
through the dense, collagen-rich capsule [13, 16-18].  A growing body of research has 
also investigated the ways in which early stage tissue response affects sensors as well.  
Table 1 outlines the different methods by which tissue effects are hypothesized to affect 
sensor function.  As such, researchers have developed different surface treatments to 
avoid specific aspects of the inflammatory process.  Examples include the following: 1.) 
coating surfaces in materials that resist protein adsorption such as Nafion, surfactants, 
and hydrogels, 2.) controlled release of anti-inflammatory therapeutics and growth 
factors such as VEGF, dexamethasone and nitric oxide, to steer the tissue to a more 
stable state and 3.) development of textured surfaces that will encourage angiogenesis 
proximal to the sensor [9, 17, 19, 20].   
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Table 1: Methods by which tissue response could alter sensor behavior 
Proposed Effect Description Citation 
Short Term (<1 week post-implantation) 
Formation of provisional 
matrix 
Coagulation cascade induces 
the formation of fibrin matrix 
clots.  These clots have been 
posited as a barrier for glucose 
diffusion to sensor and as an 
initial substrate for cell 
adhesion downstream. 
[8, 21-24] 
Signal interference by small 
molecules 
Ascorbate, urea and 
acetaminophen oxidize at 
similar voltages to hydrogen 
peroxide, causing interference 
with the sensor signal. 
[25-27] 
Effects of inflammatory cells Inflammatory cell types are 
present around sensor surface. 
They release reactive oxygen 
species and proteolytic 
enzymes, and consume local 
glucose and oxygen at 
elevated rates, thereby altering 
sensing environment.  
[16, 17, 21, 28] 
Changes in microvascular 
patterns 
After implantation, blood is 
shunted to more patent 
pathways, potentially limiting 
access to oxygen and glucose. 
[21] 
Long Term (>1 week post-implantation) 
Deposition of extracellular 
matrix 
Fibroblasts recruited to the 
area of implantation deposit a 
dense, avascular layer of 
extracellular matrix around 
the sensor, potentially 
providing a diffusive barrier 
to transport. 
[13, 18] 
Limited vascular presence The avascular barrier 
increases distances between 
the sensor and vessels, as well 
as decreasing angiogenesis. 
[13, 17] 
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2.4 Medtronic MiniMed SofSensor Continuous Glucose 
Monitoring 
All experiments described in this document will utilize Medtronic MiniMed 
SofSensor glucose sensors.  There are three electrodes present within each sensor (Figure 
2b).  The counter electrode dissipates electrons from the sensing process back into the 
environment.  The working electrode consists of multiple layers of different materials 
and is where the actual sensing of glucose occurs (Figure 2a).  The active sensing layer 
contains the enzyme glucose oxidase immobilized with human serum albumin at a 1:1 
ratio.  The actual sensing mechanism is a two step process. First, glucose oxidase 
catalyzes the oxidation of interstitial glucose to gluconic acid and hydrogen peroxide 
(Eq. 1, Figure 2b).  Secondly, a voltage is applied across the working electrode to 
decompose the hydrogen peroxide into electrons, hydrogen and oxygen (Eq. 2).  The 
generated current is then correlated by the sensor to interstitial glucose concentration.  
The top most layer of the working electrode is an exclusion membrane of polyurethane 
that allows for glucose diffusion while inhibiting the diffusion of interfering molecules 
such as ascorbic acid, uric acid, acetaminophen, and cysteine.  These molecules oxidize 
at voltages similar to hydrogen peroxide, and can obstruct sensor performance vis-à-vis 
false readings [25, 26].  
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Figure 2: (a) Schematic of layers of working electrode of the sensor. (b) Visual 
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The reference electrode maintains a constant potential between itself and the 
working electrode.  The SofSensor is connected to the Medtronic MiniLink, which 
(1) 
(2) 
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powers the sensor, collects sensor readings and wirelessly transmits data to a computer.  
The MiniLink processes the continuous signal from the sensor itself and averages it 
every one to five minutes to produce one electrical signal that correlates with interstitial 
glucose concentrations at that time. 
2.5 Inflammatory Cell Consumption of Glucose and Oxygen 
Though the effects of the implant-associated inflammatory cascade have long 
been seen as a diffusive barrier of small molecule transport to sensors, it is important to 
note that these stages also serve as bioactive barriers, as there are cells that consume 
small molecules.  Indeed, it is now being posited that inflammatory cells must 
reprogram their metabolism to increase their uptake to perform functions such as 
phagocytosis during periods of immune response [29-31].  As glucose and oxygen are 
necessary inputs for glucose oxidase activity, it is important to understand how cellular 
affinity for each is affected by implantation.  One of the most effective ways in which 
inflammatory cells like neutrophils and macrophages combat foreign objects is through 
what is known as an “oxidative attack” [32, 33].  During this process, inflammatory cells 
will generate reactive oxygen species (ROS) and reactive nitrogen species (RNS) [34].  
Specifically, ROS are generated through a “respiratory burst” in which the uptake of 
glucose and oxygen is increased to promote the production of species like the 
superoxide anion through NADPH phagosome oxidase activity.  In macrophages, the 
energy necessary to power NADPH phagosome oxidase activity is provided through the 
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increased metabolism of extracellular glucose [28, 35, 36].  As a result, there are 
increased numbers of glucose surface transporters that facilitate more pathways for 
transport into the cell for metabolism. 
The effects of in vivo macrophage activation can be mimicked in vitro through the 
treatment of potent activators.  Both LPS and PMA serve to supply macrophages with 
the extracellular signals necessary to activate them to pro-inflammatory phenotypes [37].  
LPS simulates bacterial activation of macrophages, while PMA mimics intracellular 
signaling functions of diacylglycerol [38, 39].  While each has a unique pathway to 
activation, they have been shown to produce pro-inflammatory cytokines through the 
NF-κB pathway [40, 41].  As a result of activation, both LPS and PMA treatment serve to 
upregulate glucose uptake by inflammatory cells to help them meet the large metabolic 
requirements necessary for immune response.  Both Fukuzumi, et al. and Gamelli, et al. 
showed increased levels of glucose uptake through the GLUT-1 transporter in LPS-
stimulated murine peritoneal macrophages [42, 43].  Functionally speaking, Sherry, et al. 
demonstrated the increased need for extracellular glucose during activation by showing 
that TNF-α production in LPS-stimulated macrophages from diabetic mice was 
dependent on extracellular glucose concentrations [44].  Past studies have also shown 
that treatment of a RAW 264.7 murine monocyte/macrophage cell line with the pro-
inflammatory differentiator PMA increases cellular affinity to extracellular glucose [36, 
45].  With documented cases of increased cellular consumption of glucose, it is possible 
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that ancillary effects of implant-associated inflammation are inducing an environment 
that is not conducive for sensing. 
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Chapter 3. Numerical Characterization of the Influences 
of Late Stage, Fully Formed Capsular Tissue on 
Implanted Glucose Sensor Function 
3.1 Synopsis 
Little is known mechanistically about why implanted glucose sensors lag behind 
blood glucose levels in both the time to peak sensor response and the magnitude of peak 
sensor response.  A mathematical model of glucose transport from capillaries through 
surrounding tissue to the sensor surface was constructed to address how different 
aspects of the tissue affect glucose transport to an implanted sensor.  Physiologically 
relevant values of capsule diffusion coefficient, capsule porosity, cellular glucose 
consumption, capsule thickness and subcutaneous vessel density were used as inputs to 
create simulated sensor traces that mimic experimental instances of time lag and 
concentration attenuation relative to a given blood glucose profile.  Using logarithmic 
sensitivity analysis, each parameter was analyzed to study the effect of these variables 
on both lag and attenuation.  Results identify capsule thickness as the strongest 
determinant of sensor time lag, while subcutaneous vessel density and capsule porosity 
had the largest effects on attenuation of glucose that reaches the sensor surface.  These 
findings provide concrete insight for the rational design of sensor modifications that 
may alleviate the deleterious consequences of long term tissue reactions on implanted 
sensor performance. 
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3.2 Introduction 
In order to develop a sensor that can measure glucose concentrations with high 
sensitivity for a prolonged amount of time, the interaction between the sensor and the 
surrounding tissue must be considered.  Once implanted, no sensor will exist as an inert 
object in the body since all implants will alter the surrounding environment.  However, 
minimizing the effects of the sensor on the tissue will reduce errors associated with 
inflammation.  
Figure 3a is a histological image from Yu et al. showing blood vessels embedded 
in a foreign body capsule that formed around an implanted glucose sensor two weeks 
post-implantation [18].  Hematoxylin and Eosin (H&E) staining shows the presence of 
red stained blood vessels, blue stained cells (mostly fibroblasts) and pink stained 
extracellular matrix.  Relative to cells and extracellular matrix (ECM), blood vessels 
typically occupy only a small percentage of the total tissue area surrounding an implant 
[13].  Figure 3b is an image from Koschwanez et al. showing a Masson’s trichrome stain 
of fibrous tissue that surrounded a glucose sensor three weeks post-implantation, with 
blue stained ECM, red stained cells, and no apparent evidence of vascularity [17].  Of 
particular note is the distinct layer of what are most likely inflammatory cells that lined 
the sensor surface.  While no two encapsulation tissues exhibit the exact same histology, 
they do share some common characteristics: 1.) a porous network dominated by the 
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extracellular matrix network, 2.) little to no blood vessels, and 3.) the presence of 
metabolically active cells.   
ba
 
Figure 3: (a) Histological image of a foreign body capsule that has formed 
around an implanted glucose sensor at 14 days post-implantation. H&E staining 
demonstrates lack of vasculature (red) relative to cells (blue) within capsule. Image 
borrowed from [18]. (b) Masson’s trichrome stain of a cross section of fibrous tissue 3 
weeks post-implantation.  Shows presence of extracellular matrix (blue) as well as 
cells (red) within capsule tissue.  Provides basis for modeling capsule as dense, 
avascular network composed of inflammatory cells and extracellular matrix. Image 
borrowed from [17]. 
Glucose sensors implanted or inserted in subcutaneous tissue measure interstitial 
glucose, which causes the glucose concentrations measured by the sensor to inherently 
lag behind the peak blood glucose concentration both in terms of time and amount.  
However, these effects of lag and attenuation become exacerbated over the in vivo 
lifetime of an implant.  Sensor lag time and attenuation have been thought to be 
attributable to the foreign body capsule through a number of physiological mechanisms, 
such as the presence of underdeveloped microvascular networks for limited glucose 
delivery, local glucose consumption by metabolically active inflammatory cells, and 
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decreased diffusion through the dense, collagen-rich capsule [13, 16-18].  There has also 
considerable speculation that the initial biofouling protein layer plays a significant role 
in limited sensor performance [8, 24].   
Different sensor surface modifications and drug release schemes have been 
developed to resist biofouling, attenuate inflammation, increase vascular density, and/or 
minimize foreign body capsule thickness [17, 19, 20].  However, all of these treatments 
have been developed in the absence of mechanistic understanding of how different 
aspects of the foreign body reaction affect glucose transport to the sensor surface. 
A computational model is presented that examines the effects of the 
characteristic aspects of fully formed encapsulation tissue on the transport of glucose 
from the microvessels to the surface of a subcutaneously implanted sensor after a bolus 
injection of glucose into the systemic circulation.  While others have modeled glucose 
transport through capsular tissue, the tissue has always been treated as a passive 
diffusive barrier [46, 47].  In reality, the foreign body capsule is a perfused material 
comprised of a complex porous network that is both a diffusive barrier and a bioactive 
consumer of glucose that is subject to the influence of at least five variables: foreign body 
capsule thickness, foreign body capsule porosity, blood vessel density, density of 
glucose-consuming cells and the capsular diffusion coefficient of glucose.  Greater 
understanding of these effects should lead to a more effective design of surface 
treatments intended to extend sensor performance. 
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3.3 Computational Methods 
3.3.1 Two Compartment Model 
Glucose transport through the tissue that encapsulates an implanted sensor was 
modeled as a two compartment, uni-dimensional diffusion-reaction problem (Figure 4).  
The first outer compartment modeled native subcutaneous tissue as a porous 
environment rich in blood vessels and resident mesenchymal cells (e.g. adipocytes and 
fibroblasts).  The second inner compartment modeled fibrous tissue, representing an 
avascular, porous environment with a presence of inflammatory cells.  The layer of 
adsorbed protein at the sensor surface was neglected in this analysis. 
The governing equation for glucose concentration in the outer native 
subcutaneous tissue ( tisC ) is a non-linear, uni-dimensional diffusion-reaction equation in 
cylindrical coordinates through a porous medium (Eq. 3). 
( , ) ( , )
( , )tis tis tis b tis
C r t D C r t
r Q r t
t r r r
 ∂ ∂∂ = +Φ −  ∂ ∂ ∂
                             (3) 
bΦ  and tisQ  represent the rate of glucose transport from the lumen of 
microvessels to the interstitial space of the subcutaneous tissue and the consumption 
rate of glucose by native adipocytes in the subcutaneous space.  bΦ  is defined as the rate 
of glucose transport per unit volume from blood vessels into the interstitial space of the 
tissue, making it the source of glucose for the tissue compartment.  It is described by a 
modified version of the Kedem-Katchalsky equation, where P  is the microvascular 
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permeability of the vessel wall to glucose (cm/sec), 
S
V
 is the density of blood vessels in 
terms of the microvessel surface area per unit volume of the tissue (cm2/cm3), pC  is the 
concentration of glucose in the blood (µmol/ cm3), and tisε  is the porosity of the native 
tissue (unitless) (Eq. 4) [48]. 
( , )
( ) tisb p
tis
C r tPS
C t
V ε
  Φ = −   
                                                       (4) 
tisQ  is defined as the uptake of glucose by native adipocytes and is represented 
by Michaelis-Menten kinetics, where max,tisV  is the maximum rate of glucose 
consumption (µmol/(cell-sec)), ,M tisK  is the Michaelis constant (µmol/L), tisε  is the 
porosity of the native tissue (unitless), and cellz  is the volume of a native cell (L/cell) (Eq. 
5) [28].  This term represents a glucose sink, as uptake of the analyte by cells removes it 
from the system. 
max,
,
( , ) 1
( , )
( , )
tis tis tis
tis
M tis tis tis cell
V C r t
Q r t
K C r t z
ε
ε
 −  =   +  
                                           (5) 
The inner fibrous capsule compartment was modeled as an avascular area, which 
is consistent with histological findings that show a decreased presence of blood vessels 
relative to native tissue [47].  As a result, the governing equation describing glucose 
concentration in the fibrous capsule ( FBCC ) (Eq. 6) has no source term in addition to the 
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diffusion terms, and only a sink term to describe uptake by inflammatory macrophages 
that is similar to the uptake expression in the native tissue compartment. 
( , ) ( , )
( , )FBC FBC FBC FBC
C r t D C r t
r Q r t
t r r r
 ∂ ∂∂ = −  ∂ ∂ ∂
                                  (6) 
FBCQ  is defined as the rate of glucose uptake by inflammatory macrophages in 
the capsule and is modeled by Michaelis-Menten kinetics, where max,FBCV  is the 
maximum rate of consumption (µmol/(cell-sec)), ,M FBCK  is the Michaelis constant 
(µmol/ L), FBCε  is the porosity of the native tissue (unitless), and cellz  is the volume of an 
inflammatory cell (L/cell) (Eq. 7) [49].  This term represents a glucose sink in the capsule, 
as uptake of the analyte by cells removes it from the system. 
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Figure 4: Schematic representation of model for diffusion of glucose through 
native tissue and the fibrous capsule. 
3.3.2 Initial and Boundary Conditions 
For the initial condition, it was assumed that the diffusion time in the tissue was 
much shorter than the time scale of simulation.  The initial condition for the system was 
a vector that was output when running the simulation for a baseline input concentration 
before the fitted blood glucose bolus was input. 
Boundary conditions were specified at the sensor surface (r=a), the interface 
between the tissue and capsule compartments (r=a+L), and a location far away from the 
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sensor (r→∞).  At the sensor surface, the rate of glucose diffusion in the capsule 
compartment is equal to the rate of glucose uptake by the sensor, sensorQ  (Eq. 8).  It was 
assumed that the consumption rate was proportional to the glucose concentration at the 
sensor surface with λ being the proportionality constant (mol/(mM-sec)).  The sensitivity 
of the sensor to glucose may decay with time.  To account for this occurrence, a 
nondimensional parameter, α, was introduced.  It is defined as the sensor efficiency and 
ranges from zero to unity.  For this case, the sensor is assumed to be perfectly efficient, 
with α=1. sensorA  is defined as the total surface area of the sensor available for glucose 
transport and a is the radius of the sensor [50]. 
( , )
( , )FBC FBCFBC sensor sensor
FBC
C C r a t
D A r a t Q
r
αλ
ε
∂ =
= = =
∂
                         (8) 
At the interface between the tissue and capsule compartments, it is assumed that 
glucose is conserved and no glucose accumulates or disappears at the interface, so both 
concentrations and fluxes are matched (Eqs. 9 and 10). 
( , ) ( , )FBC tis
FBC tis
C r a L t C r a L t
ε ε
= + = +
=                                                 (9) 
( ) ( ), ,FBC tisFBC tis
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D r a L t D r a L t
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= + = = +
∂ ∂
                                    (10) 
In tissues far away from the sensor, it is assumed that the concentration in the 
tissue is the same as that in the blood (Eq. 11). 
( , ) ( )tis pC t r C tε→∞ =                                                       (11) 
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3.3.3 Blood Glucose Concentration 
Blood glucose profiles used in simulations were numerical fits of actual 
experimental intravascular glucose infusion data taken from the published literature.  
The glucose infusion and sensor response data of Koschwanez et al. were employed to 
demonstrate that the program generated realistic dose-response behavior of a 
subcutaneously implanted sensor [17].  For parametric sensitivity analysis the glucose 
infusion data of Armour, et al. were employed because the blood glucose data are from 
an intravascular sensor that may measure instantaneous changes in blood glucose more 
reliably than data from a discrete finger prick test [51].  The raw infusion data from 
Armour et al. were fit to a sum of three Gaussian curves (Eq. 12). The fitted values for 
the constants in Eq. 12 are given in Table 2.  
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Table 2: Fitted parameters from raw data of Armour, et al. for blood glucose 
expression in Eq. 12 [51]. 
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c3c2c1b3b2b1a3a2a1
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3.3.4 Transport and Kinetic Parameters 
In order to accurately mimic a fully formed capsule, the physiologically relevant 
values of model constants listed in Table 3 were used in numerical simulations.  
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However, it should be noted that chronic inflammation and wound healing processes 
may lead to changes in these values; a condition that was not considered in this study. 
Diffusion coefficient values ( D ) were obtained from the study of glucose 
transport in subcutaneous tissue and the fibrous capsule, respectively.  The maxV  and 
MK  values in the capsule were based upon the data of macrophage uptake of glucose 
while those in the native tissue were based upon adipocyte uptake of glucose, thereby 
accounting for the fatty nature of the human subcutis.  Capsule thicknesses ( L ) vary 
based upon the type of implant, how it is implanted, and what is classified as a foreign 
body capsule.  Results for subcutaneously implanted sensors can vary anywhere from 30 
to 750 µm, in extreme cases [12, 18, 47].  The thickness was chosen to be 75 µm since it 
was a typical value for a well formed capsule.  The surface area of the sensor was 
measured for a Medtronic MiniMed sensor. 
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Table 3: List of all baseline model parameters. Values listed with * in the 
citation column are model assumptions while those listed with ** are calculated 
values with no previous citation. 
Parameter Values Model Parameters 
FBC Native Tissue Citation 
Diffusion Coefficient 
(D) (cm2/sec) 
1.87x10-6 3.5x10-6 [47] 
Porosity (ε) (unitless) 0.5 0.6 * 
Vessel Density (S/V)          
(cm2/cm3) 
- 15.4 [50] 
Capsule Thickness (L) 
(µm) 
75 - [12, 18, 47] 
Michaelis Constant 
(KM) (µM) 
6.13x103 6.2x103 [28, 49] 
Maximal rate of 
cellular glucose 
uptake (Vmax) 
(µmol/(cell-sec)) 
4.88x10-11 3x10-11 [28, 49] 
Vascular glucose 
permeability (P) 
(cm/sec) 
- 5x10-5 [48] 
Conversion constant                      
(λ) (mol/(mM-sec)) 
2.574x10-14 - ** 
Cell Volume (zcell) 
(L/cell) 
9.5x10-13 9.5x10-13 * 
Glucose Sensor 
Radius (a) (cm) 
0.07 - [50] 
Sensor Surface  Area 
(A) (cm2) 
0.0058 - [50] 
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3.3.5 Parametric Sensitivity Analysis 
Aspects of the fibrous capsule that had the greatest effect on either time lag or 
sensor signal attenuation were determined by running the simulation for a range of 
values for each parameter, while keeping all other parameters constant.  The parameters 
to be considered were capsule diffusion coefficient ( FBCD ), capsule porosity ( FBCε ), 
vessel surface area per unit volume of subcutaneous tissue (
S
V
), maximum rate of 
glucose uptake by macrophages ( max,FBCV ) and capsule thickness ( L ).  Table 4 shows the 
range of values that were input for the sensitivity study.  For every simulation that was 
executed for a value of a given parameter, the model computed both an associated 
output lag time and an attenuation value.  Therefore, for an input range of N values of a 
given parameter, there would be N associated lag times and N associated attenuation 
values. 
The sensitivities of these output values to their input values of the model 
parameters were calculated using logarithmic sensitivity analysis [52].  The 
representative equation for a logarithmic sensitivity, iS , of an output value, l , for a given 
input parameter, x , is given in Eq. 13. 
i
i
i
xl
S
x l
∆
=
∆
                                                             (13) 
l∆  is defined as the difference between outputs over the range of input values 
and x∆  is defined as the difference between the input values.  ix  is defined as the 
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midpoint of the input range, and il  is the output associated with the input, ix .  For a 
range of input and output values, one could calculate a range of sensitivities by 
decreasing x∆ .  By calculating sensitivity in this way, the differences in absolute 
magnitude are not considered. Instead, only the relative change in response to the 
relative change in the input is considered. 
For this specific series of simulations, ranges of values for the capsule diffusion 
coefficient ( FBCD ), capsule porosity ( FBCε ), subcutaneous vessel density (
S
V
), cellular 
uptake of glucose ( max,FBCV ), and capsule thickness were entered into the model.  When 
testing one parameter, all others were held constant to see how the changes within each 
parameter affect simulated sensor performance.   
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Table 4: Range of different parameters to be used for sensititivity analysis.  
Bolded values represent benchmark values from Table 3. 
7501202.44x10-100.93.74x10-65
-166.34.88x10-10--6
375609.76x10-110.81.87x10-64
15015.44.88x10-110.69.35x10-73
7552.44x10-110.43.74x10-72
1524.88x10-120.21.87x10-71
Capsule 
Thickness 
(µm)
Vessel 
Density 
(cm2/cm3)
Vmax,FBC
(µmol/(cell-
sec))
εFBC
(unitless)
DFBC
(cm2/sec)
Parameters
 
3.3.6 Assessing Glucose Sensor Performance 
Lag times were calculated as the difference between the time at which glucose 
concentration peaked in the blood glucose profile and the time glucose concentration 
peaked at the sensor surface.  Attenuation of glucose concentration due to capsule 
formation was calculated as one minus the ratio of the peak sensor surface value divided 
by the peak blood glucose value (Eq. 14).   
{ }
{ }
max ( , )
1
max ( )
FBC
P
C t r a
Attenuation
C t
=
= −                                      (14) 
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3.3.7 Numerical Methods 
The governing partial differential equations were discretized into a series of 
ordinary differential equations using the finite difference method.  These discretized 
equations were then solved using the differential equation solver, ode15s, in MATLAB 
(The Mathworks, Natick, MA).  Curve fitting for the blood glucose profile was 
performed using the Curve Fitting Toolbox in MATLAB. 
3.4 Results 
3.4.1 Numerical Approximation of In Vivo Experimental Sensor Data 
The individual data points in Figure 5 are rat tail prick blood glucose values 
following a tail vein injection of 0.5 mL of 50% dextrose measured using a commercial 
blood glucose meter (●), and the corresponding values from a MiniMed sensor 
implanted for 24 hours in the dorsal subcutis of the same rat as reported by 
Koschwanez, et al. (■) [17].   The dashed line superimposed on the experimental blood 
glucose values (-·-) is the best fit of Eq. 12 to the blood glucose values, which was then 
used as a model input to generate the simulated glucose sensor response (--).  This trace 
can then be compared to the solid line fitted to the experimental sensor data.  Figure 5 
also indicates the sensor time lag (∆test) and the sensor attenuation (∆Cest) for the 
simulated data that was used in subsequent sensitivity analyses.  The experimental lag 
(∆texp) and attenuation (∆Cexp) from Koschwanez, et al. are also reported in Figure 5 [17]. 
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Overall, Figure 5 shows that the program was able to approximate the temporal 
profile of the experimental data from the implanted sensor.  The simulated sensor 
response has a lag time of ~3 minutes and the sensor signal was 76% of the blood 
glucose signal for a signal attenuation of 24% [17].  With regards to attenuation, the 
simulated trace only minimally overestimates attenuation, producing a peak that is 97% 
of the measured sensor peak.  Lag times are less similar between the experimental and 
simulated data, with the simulated trace recording a lag of 2.87 minutes, 
underestimating the experimental lag of 5.28 minutes.  It should be noted that 
attenuation and lag are less pronounced in this simulation because model parameters 
were based upon the local environment at 24 hours post-implantation, which is before a 
mature capsule has formed.  While subsequent studies in this chapter will describe 
transport through a fully formed capsule, this example demonstrates the ability of the 
model to describe different temporal regimes of the post implantation environment 
when compared to experimental data. 
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Figure 5: Simulated recreation of experimental glucose sensor traces.  Raw 
blood glucose data (●) was fit to a continuous curve, ,expbg erimentalC , (-●-) and then input 
into the model to give a simulated glucose sensor trace, ,mods elC , (--).  This output was 
compared in shape to raw sensor data (■), which is fit by a solid line, ,exps erimentalC .  The 
simulated trace produced a lag time (Δtest) and attenuation (ΔCest) and a shape similar 
to data in Koschwanez, et al [17].  The lag time and attenuation from [17] are 
represented in Figure 5 by Δtexp and ΔCexp. 
3.4.2 Sensor Lag Time and Attenuation of Glucose Concentration 
Values of time lag and glucose attenuation were calculated using the 
physiologically representative literature values in Table 3 where five of these variables – 
capsule diffusion coefficient, capsule porosity, maximum cellular uptake rate for glucose 
in the capsule, vascular density in surrounding native tissue, or the capsule thickness – 
were allowed to vary independently as listed in Table 4.  These calculations resulted in 
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the set of five plots presented in Figure 6.  In each case, the results were normalized to 
the benchmark values of time lag and attenuation calculated using the Table 3 values.  
This normalization allowed direct comparison of the fractional effects of independently 
varying one of the five parameters listed in Table 4. 
Figure 6 shows the relative effects of varying (a) the capsule diffusion coefficient, 
(b) the capsule porosity, (c) the vascular density in surrounding native tissue, (d) the 
cellular uptake of glucose in the capsule, and (e) the capsule thickness on sensor time lag 
and attenuation. 
Increased capsule diffusion coefficient, capsule porosity, and vessel density all 
lessened attenuation of peak glucose concentration at the sensor surface.  Conversely, 
increased cellular uptake of glucose in the capsule and capsule thickness both increased 
attenuation of peak glucose concentration at the sensor surface.  In this case, changes in 
the diffusion coefficient and cellular uptake both had only modest effects.  Lag times 
were found to increase with increases in porosity and capsule thickness as well as 
decreases in vessel density and diffusion coefficient.  Changes in cellular uptake 
produced negligible changes in lag. 
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Figure 6: Effect of (a) capsule diffusion coefficient, (b) capsule porosity, (c) 
vascular density in surrounding native tissue, (d) cellular uptake of glucose in the 
capsule, and (e) the capsule thickness on sensor lag times (-●-) and attenuation (--●--) 
Results have been normalized to baseline values in Table 3. 
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3.4.3 Lag Time and Attenuation Sensitivity Analysis 
Logarithmic sensitivity analysis was used to determine the sensitivity of a 
dependent variable, such as lag or attenuation, to variation in one independent variable 
while holding all other independent variables constant.  Figure 7 shows box and whisker 
plots of logarithmic sensitivities for (a) normalized lag times and (b) normalized glucose 
attenuation values as functions of the five independent variables listed in Table 4.  
Sensor lag time was shown to be highly sensitive to changes in capsule thickness, 
while only mildly sensitive to the other four variables.  The minimum sensitivity due to 
capsule thickness change (0.4828) was more than twice that of the maximum sensitivity 
from the next highest value due capsule porosity change (0.2307).   
The attenuation of blood glucose as it is transported to the sensor surface was 
most sensitive to two variables: the vessel density of the subcutaneous tissue and the 
capsule porosity.  Glucose attenuation also appears to be mildly sensitive to capsule 
thickness, and essentially insensitive to capsule diffusion coefficient and cellular glucose 
uptake. Although vessel density did have the highest maximal sensitivity value of 1.01, 
it had a lower mean sensitivity than capsule porosity, and a minimum sensitivity value 
of 0.0515 that was similar in magnitude to the less sensitive parameters of capsule 
thickness, capsule diffusion coefficient and cellular glucose uptake.  
Interestingly, increasing capsule thickness had a pronounced effect on increasing 
sensor lag time, but capsule thickness had only a modest effect on glucose attenuation; 
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whereas increasing either vessel density or capsule porosity had pronounced effects on 
decreasing glucose attenuation, but neither vessel density nor capsule porosity had 
appreciable effects on sensor lag time.  Furthermore, both sensor lag time and glucose 
attenuation were essentially insensitive to cellular uptake of glucose. 
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Figure 7: (a) Box and whisker plots of lag sensitivity to five different model 
parameters. (b) Box and whisker plots of attenuation sensitivity to five different 
model parameters. Sensitivities are represented as unitless values to allow for 
comparison across parameters. 
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3.5 Discussion 
Experimental studies have shown that if an implanted glucose sensor can 
withstand the 7-14 days that it normally takes to form a stable fibrous capsule, then it is 
more likely to remain functional in the body for months [53].  The current study used a 
transport model to simulate the behavior of an implanted glucose sensor surrounded by 
a fibrous foreign body capsule.  The primary advantage of the modeling approach over 
experimentation was the ability to evaluate the effects of individual physiological 
parameters on glucose sensor response.   
The goal of this study was twofold: 1) demonstrate that the transport model 
accurately reproduces implanted glucose sensor response by incorporating 
physiologically relevant tissue parameters, and 2) use the model to gain insight into 
aspects of the fibrous capsule and the surrounding tissue that most affect sensor lag time 
and glucose signal attenuation.  
The suitability of the transport model was demonstrated by generating a 
simulated implanted glucose sensor response using a blood glucose profile from 
Koschwanez et al. as the input (Figure 5) [17].  The simulated sensor output was 
compared to the actual implanted sensor response to the input blood glucose profile.  
The model was able to reproduce the shape of the implanted sensor trace with an 
attenuation and lag time that are comparable to experimental data.    
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Table 3 lists the physiological modeling parameters used to describe a mature 
fibrous capsule that would surround a sensor a few weeks following subcutaneous 
implantation.  These values were used to generate a benchmark simulated sensor 
response for the sensitivity studies.  Vessel densities were based on measured values at 3 
weeks post implantation in the subcutaneous tissue of rats.  Cell metabolic values were 
based on those of macrophages, which are the dominant cell type in the fibrous capsule 
at that time.  Capsule thicknesses were similarly based upon reported values at 3 weeks 
post implantation, though thickness values vary considerably across the literature due to 
what is considered a capsule during experiments. 
It should be noted that the biofouling layer was neglected in the simulations.  
Generally this stratum of protein and protein fragments ranges from 20 nm to 0.5 µm in 
thickness, which creates a negligible effect on transport, even when its permeability to 
glucose is drastically decreased (data shown in Chapter 4).  These findings further 
support findings from Wisniewski et al. who found that the surrounding fully 
developed capsular tissue offered substantially greater resistance to glucose transport 
than the biofouling layer [8].  While many believe that the proteins and proteolyic 
enzymes within the biofouling layer can damage the glucose-sensitive membranes on 
sensor electrodes, those assertions are outside the scope of this study, which only 
considers biofouling from a transport perspective.   
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The transport model was utilized to examine how capsule formation affects the 
onset of lag times and signal attenuation.  When exposed to a range of values for the five 
parameters of interest, lag times were most affected by changes to the thickness of the 
capsule.  Lag times steadily increased in a linear fashion over a range of thicknesses.  
Such an effect upon lag time should be expected.  First, a thicker capsule translates to 
larger length scale that allows for more random routes for transport of glucose 
molecules to the sensor surface [54].  Second, since the capsule was assumed to be 
avascular, the distance between source blood vessels and the target sensor has been 
increased.  Therefore, capsule thickness cannot affect how much glucose is in the system 
but instead can only affect how fast the glucose reaches the sensor.  By comparison, 
changes in lag time were not affected appreciably by changes in capsule porosity, 
capsule diffusion coefficient, or cellular uptake of glucose.  From a biological 
perspective, this implies that the physical thickness of the capsule mattered more to 
inducing the lag time than did changes in the constituent parts of the capsule.   
With respect to attenuation, capsule porosity and vessel density were found to 
have the largest effects on sensor response, though these ranges of sensitivities exhibited 
greater spread than those values in the lag time study.  Attenuation sensitivity to vessel 
density ranged from an essentially insensitive factor of 0.0515 for low vessel densities to 
the most highly impactful factor for all parameters of 1.01.  This finding is intuitive as 
blood vessels in the subcutaneous tissue are the only source of glucose in the model; 
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therefore a reduction in the source of glucose translates into a decreased amount of 
glucose that can even reach the sensor. The vessel density findings corroborate those of 
Sharkawy and Koschwanez, who have found that the presence of vessels can extend the 
useful life of the sensor [17, 55]. 
Comparatively, the influence of capsule porosity on attenuation had a higher 
median sensitivity and narrower range of sensitivities, suggesting that it had a more 
consistent effect on attenuation than did vessel density.  Low capsule porosity increased 
glucose attenuation because it reduced transport pathways, resulting in a diminished 
amount of glucose molecules reaching the sensor surface and an accumulation of 
glucose in the native tissue. 
It is interesting to note that high vessel density and high porosity have similar 
effects on glucose attenuation: porosity exhibits high attenuation sensitivity at high 
porosities ( 0.6FBCε > ) and vessel density exhibits high attenuation sensitivity at high 
vessel densities ( 160S cm
V
−> ), both of which are likely to occur early following 
implantation.  As capsule formation occurs, the capsule goes from a loosely organized 
protein and cell layer to a highly dense layer of cells and extracellular matrix.  Therefore, 
the high sensitivity at high porosities denotes that capsule porosity has a large effect on 
attenuation at points early in the capsule formation process.  Similarly, peak attenuation 
sensitivity occurs at vessel densities near pre-implantation values, which would indicate 
that it affects attenuation early in the capsule formation process as well.  This finding 
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suggests an initial synergistic effect of both the changing porosity and changing vessel 
density on attenuating sensor response early in the capsule process.  However, as vessel 
density decreases through capsule formation, so does its sensitivity to attenuation, 
reaching a minimum at 0.0515.  Though sensitivity due to capsule porosity also 
decreases as the capsule forming process continues and porosity decreases, its minimum 
is still much higher (0.278) than the maximum values of other parameters.  For later 
times in capsule formation, porosity continues to dominate attenuation sensitivity.  So, 
attenuation sensitivity is initially affected by both vessel density and capsule porosity, 
with porosity dictating attenuation as the capsule continues to grow. 
Ultimately, we are interested in the conditions that generate the best scenario for 
glucose transport to an implanted sensor.  Figure 8 is a scatter plot that summarizes all 
of the lag time and glucose attenuation values generated for all of the conditions tested 
using the computational model.  Vessel Density (green), capsule porosity (blue) and 
capsule thickness (red) were labeled to see the lag time and attenuation trends among 
the highly sensitive model parameters.  The benchmark point determined using the 
baseline values in Table 3 is labeled in magenta and represents the intersection of all 
other points in the simulation.   
The quadrant on the bottom left of Figure 8 represents low attenuation (<0.5) and 
low lag (<5 min).  Of all the conditions entered into the model, only vessel density 
between 60 and 166.3 cm2/cm3 produced a low attenuation and low lag environment.  
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Attenuation dropped four fold from nearly avascular conditions to a highly vascular 
tissue typical of subcutaneous tissue.  This finding demonstrates the importance that 
adequate vessel density has on effective implantable sensor readings in vivo and 
corroborates previous assertions by Ward et al. about the importance of vasculature in 
sensor performance [56].  The upper right quadrant represents the worst case scenario of 
high lag time and high attenuation.  Only high capsule thicknesses generated this 
situation with lag times increasing steadily from nearly 0 sec to nearly 10 minutes with a 
50-fold increase in capsule thicknesses, further showing the deleterious effects of a thick 
capsule on sensor performance.  Most results resided in the upper left quadrant of low 
lag and high attenuation, suggesting that most of the conditions tested affected 
attenuation more than lag time.  Thus, lag was attributed almost exclusively to capsule 
thickness, while attenuation was affected by multiple factors.  No points resided in the 
lower right quadrant, suggesting that changes in the model parameters will not create a 
situation where a sensor will have a high lag time and low attenuation.   
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Figure 8: Scatter plot of sensor time lag v. glucose attenuation for all of the 
conditions simulated with the transport model.  The three variables that showed the 
greatest sensitivity – capsule thickness, vessel density and capsule porosity – are 
represented by the red, green and blue circles, respectively.  The benchmark value of 
time lag and attenuation calculated using the variables in Table 3 is labeled in 
magenta. This data point is common to all simulation trials.  The open circles 
clustered around the benchmark value are the results obtained for the less sensitive 
variables of capsule diffusion coefficient and cellular glucose uptake. 
Finally, this modeling study made two key assumptions: 1) that each parametric 
variable could be changed independently without affecting the others, and 2) that the 
system can be described as a straightforward two compartment transport model.  
 47 
Clearly, the assumption of variable independence is problematic because a number of 
transport parameters are in fact interrelated.  For example, the diffusion coefficient for 
the capsule is not just the diffusion coefficient of glucose in the void space of the capsule, 
but the effective diffusion coefficient of glucose in the capsule matrix that would be 
affected by altering the porosity or the cellular glucose uptake.  However, this study is 
just asking what happens when one parameter is changed.  This study is more 
concerned with what happens to the output when a parameter changes, not necessarily 
how it changes constituent parts. 
The possible omission of additional mitigating variables from the model is also 
of concern.  This finding may be most apparent in that most conditions yielded a lag 
time of approximately 2 minutes, except for cases of very thin or very thick capsules.  
Such a finding is in contrast to the 5 minutes or longer time lags typically reported in the 
literature for implanted glucose sensors, even in cases where the sensor has been 
implanted for short time periods before any fibrous capsule could form.  This may 
suggest that factors like metabolic activity of inflammatory cells should be taken into 
greater account in future iterations.  An additional factor that may help to account for 
time lag is the change in microcirculation patterns in tissues during inflammation and 
wound healing.  Besides the obvious changes in vessel density, there is also a decrease in 
the length and diameter of vasculature in wound healing tissue as well as a decrease in 
red blood cell velocity [57].  Smaller diameters of the existing vessels in the tissue will 
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create a higher resistance to blood flow and may shunt blood flow to a different 
collection of vessels.  Therefore, not only the number of patent blood vessels, but also the 
geometry of those vessels will affect the delivery of glucose to the subcutaneous space.  
Future computational studies will have to account for such changes to create a more 
complete portrait of the post-implantation environment.  
3.6 Conclusions 
This study describes a computational model of glucose transport through native 
tissue and across a mature foreign body capsule to a sensor surface that was used to 
examine how different transport parameters affect long term sensor time lag and 
attenuation of glucose to reach the sensor surface.  Sensitivity analysis shows that when 
considering a fully formed capsule, sensor lag is mainly attributable to changes in 
capsule thickness and sensor attenuation is primarily affected by changes in vessel 
density and capsule porosity.  Another interesting point was the observation that the 
capsule diffusion coefficient and cellular uptake of glucose did not affect the different 
modes of sensor failure once the capsule has been fully formed.  To exclude certain 
features of capsule formation will allow for more focused designs and experiments in 
the future.  Therefore, the work presented here should promote more rational design of 
modified sensor surfaces to control immune responses, ultimately extending the useful 
life of implantable glucose sensors. 
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Chapter 4. Characterization of the Early Stage Effects of 
Implantation on Glucose Sensor Performance 
4.1 Synopsis 
While the effects of fully formed capsular tissue on sensor response have been 
addressed in Chapter 3, there has been little done to understand how tissue interactions 
occurring before mature capsule formation hinder sensor performance.  The goal of this 
chapter is to provide a mechanistic understanding of the effects of early stage tissue 
reactions on implanted glucose sensor function. When taken in concert with the results 
of Chapter 3, these findings will provide a more complete temporal profile of the 
interactions between the sensor and the surrounding tissue as well as consequential 
downstream outcomes on sensor response. 
Upon insertion in subcutaneous tissue the sensor is bathed in blood.  Using 
human whole blood as a simple ex vivo experimental system, the impacts of protein 
accumulation at the sensor surface (biofouling effects) and cellular consumption of 
glucose in both the biofouling layer and in the bulk (metabolic effects) on sensor 
response were assessed.   
To this end, Medtronic Minimed SofSensor glucose sensors were incubated in 
whole blood, plasma diluted whole blood, and cell-free platelet poor plasma (PPP) to 
analyze the effects of different blood constituents on sensor function.  Experimental 
conditions were then simulated using MATLAB to predict the relative impacts of 
biofouling and metabolic effects on the observed sensor responses. 
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It was found that the physical barrier to glucose transport presented by protein 
biofouling does not hinder glucose movement to the sensor surface. Moreover, the 
consumption of glucose by inflammatory cells, and not erythrocytes, proximal to the 
sensor surface had a substantial effect on sensor response and may be the main culprit 
for anomalous sensor behavior immediately following implantation. 
4.2 Introduction 
In order to bring a more complete description to sensor behavior in 
subcutaneous tissue, the author previously presented a computational transport model 
to elucidate the effects that constituent parts of fully formed capsular tissue have upon a 
transcutaneous sensor’s ability to accurately measure glucose values in real time [58].  
However, a more complete understanding of the effects of tissue interactions on sensor 
function should also include events that occur prior to mature capsule formation.  
Clinically, this time frame is of particular importance because it coincides with the 3-7 
day window of FDA approval for all commercially available continuous glucose 
monitoring systems [6, 7, 59, 60].   
Upon insertion these sensors are bathed in blood and the sensor surface becomes 
fouled with blood plasma proteins and blood borne cells.  Klueh, et al. recently reported 
a series of experiments using sensors from both Abbott Diabetes Care and DexCom that 
examined this interaction by immersing transcutaneous sensors in unheparinized and 
heparinized whole blood.  All of the sensors exhibited a temporal decay in glucose 
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signal, which they attributed to glucose consumption by erythrocytes accumulated at 
the sensor surface [23].  More recently, this group conducted in vivo studies on the role 
of erythrocyte embedded clots on sensor function in mice [61]. 
Similar to Klueh, et al., in the current study, the effects of protein biofouling and 
cellular accumulation were observed experimentally by recording the changes in 
response of commercially available Medtronic MiniMed SofSensors in heparinized 
whole blood and various blood constituents.  Numerical simulations were then used to 
further predict physiological scenarios that could be used to explain the experimental 
observations.   
4.3 Materials and Methods 
4.3.1 Blood Sample Preparation 
In accordance with IRB protocol 2257-08-1R17ER, samples of human blood from 
healthy volunteers were collected in 10 mL vacutainers containing EDTA to prevent 
immediate coagulation.  Upon collection, samples were immediately used for studies, as 
platelet counts have been shown to decrease by over 50% after 72 hours ex vivo [62].  
Extra measure was taken to further ensure that no coagulation takes place by adding a 
heparin sulfate stock solution at 100 U/mL in PBS (-/-) to the blood to achieve a final 
heparin concentration of 5 U/mL.  This final concentration is higher than the 
recommended dosage for treatment of 0.4 U/mL to ensure a well-stirred solution for the 
subsequent long term studies [63]. 
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Blood constituent samples were prepared through the fractionation of blood via 
centrifugation using an existing protocol from Weibrich, et al. to gather platelet rich 
plasma (PRP) and PPP for studies.  PRP is the volume of blood that is absent 
erythrocytes and leukocytes but contains platelets, small molecules and plasma proteins.  
PPP, however, contains only small molecules and plasma proteins.  PRP was obtained 
from centrifuging whole blood for 10 minutes at 1500 rpm and then removing the 
hematocrit.  PPP was obtained from centrifuging PRP for 15 minutes at 3600 rpm to 
remove the platelets.  By having different constituents of blood, the contributions of both 
the plasma and whole blood to sensor function could be delineated.   
Plasma diluted blood was prepared as a 1:11 dilution of whole blood in its own 
plasma.  This dilution produced a cell concentration of 5x105 cells/mL, which is a 
common value for white blood cell concentrations in whole blood [64].  PPP was chosen 
for the blood diluent as it should not dilute the glucose concentration of the sample 
while diluting the cell concentration.  
4.3.2 Glucose Sensor Calibration 
Two Medtronic SofSensors (Medtronic Diabetes Care, Northridge, CA) were first 
immersed in a stirred PBS bath at 37oC initially at 0 mg/dL glucose.  To calibrate each 
sensor, glucose was added to increase the concentration to 100 mg/dL and a baseline 
current was allowed to form.  This step was then repeated for 200 mg/dL of glucose.  
From these three data points (0, 100, 200 mg/dL glucose), a linear calibration curve 
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relating glucose concentration to sensor output current could be made.  Besides allowing 
for concentration readings, this calibration step served as a check that the sensors were 
properly working, as the sensors were reported by the manufacturer to have a linear 
response to glucose incursions for a range of 0-400 mg/dL glucose.   
4.3.3 Whole Blood and PPP Studies 
Once calibration was completed, the sensors were transferred from the PBS bath 
to one of two 10 mL samples of either gently stirred whole blood or PPP at 37oC.  This 
incubation was carried out until a baseline was formed, which took about 10 hours.  
During the ten hour incubation, blood and PPP glucose concentrations were measured 
periodically via test strips (OneTouch Ultra, Johnson & Johnson, Milpita, CA) to ensure 
that the sensors were accurately recording trends in each test group.  To examine 
whether blood and PPP allow sensors to behave in a stepwise, nonreactive fashion like 
PBS, glucose incursions were made to double the glucose in the system.  Sensors were 
then allowed to gather a baseline over six hours and the process was repeated.  Test strip 
measurements were made at the beginning and the end of each incursion to see if sensor 
response mimicked a direct blood glucose concentration measurement.  After the blood 
incubation, both sensors were “post-calibrated” in a stirred PBS bath at 37oC using the 
same process as the pre-calibration.  This study was repeated three times (n=3). 
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4.3.4 Whole and Dilute Blood Studies 
To examine the effect of cell number and consumption upon sensor readings, 
sensors were immersed in both whole and dilute blood.  After the same PBS calibration 
step described above in §4.3.2, two sensors were submerged in one of two test solutions.  
The first solution was heparinized whole blood prepared as described in §4.3.1.  The 
second solution was blood diluted 1:11 in its own PPP, which should not dilute the 
glucose concentration of the sample while diluting the cell concentration.  The sensor 
treatment protocol followed the same layout as in §4.3.2 and  §4.3.3.  This study was 
repeated three times (n=3). 
4.3.5 Data Collection, Calibration and Statistical Analysis 
All sensor signals were sorted and plotted using custom scripts written in 
MATLAB (The Mathworks, Natick, MA).  Calibration curves were calculated as a linear 
fit by using the “polyfit” command in MATLAB.  An analysis of covariance (ANCOVA) 
was performed in MATLAB to assess significant differences in the slopes of the linear 
portions of the sensor signal during incubation in different blood constituents (p<0.05). 
4.3.6 Computational Modeling of Cellular Glucose Consumption 
To complement experimental findings, a numerical simulation of the 
experimental setup above was derived and implemented using MATLAB.  Figure 9 
presents a schematic representation of the model used in this study, which was modified 
from the model presented in a previous article by this group [58].  Briefly, transport of 
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glucose through the environment surrounding the sensor was treated as a two 
compartment construct.  The first compartment, the one closer to the sensor with respect 
to distance, was the biofouling layer (Clayer), a thin layer of proteins and 
adherent/entrapped cells that forms in within minutes of blood exposure.  The second 
compartment (Cbulk) was the bulk blood surrounding the sensor and its biofouling layer.  
Values for all constants are defined in Table 5. 
4.3.6.1 Governing Equations 
The governing equation describing glucose concentration in the cellular region of 
the biofouling layer (Clayer) is a non-linear, uni-dimensional diffusion-reaction equation 
in cylindrical coordinates through a porous medium. It has a diffusion term and a sink 
term to describe uptake by adherent cells (Eq. 15)  
( , ) ( , )
( , )
layer layer layer
layer
C r t D C r t
r Q r t
t r r r
 ∂ ∂∂  = −  ∂ ∂ ∂ 
                         (15) 
Qlayer is defined as the rate of glucose uptake by cells in the layer and is modeled 
by Michaelis-Menten kinetics, where Vmax,layer is the maximum rate of consumption 
(µmol/(cell-sec)), KM,layer is the Michaelis-Menten constant (µmol/ L), εlayer is the porosity 
of the biofouling layer (unitless), and zcell is the volume of a cell within the layer (L/cell) 
(Eq. 16).  In this model, the fibrin network and cells were assumed to be well mixed 
within the biofouling layer.  Therefore, they were not considered separately. 
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The governing equation for glucose concentration in the bulk blood (Cbulk) is a 
non-linear, uni-dimensional diffusion-reaction equation in cylindrical coordinates 
through a porous medium (Eq. 17). 
( , ) ( , )
( , )bulk bulk bulk bulk
C r t D C r t
r Q r t
t r r r
 ∂ ∂∂ = −  ∂ ∂ ∂
                          (17) 
Qbulk represents the consumption rate of glucose by native red blood cells in the 
bulk space and is modeled with Michaelis-Menten kinetics as well, where Vmax,bulk is the 
maximum rate of glucose consumption (µmol/(cell-sec)), KM,bulk is the Michaelis-Menten 
constant (µmol/L),εbulk is the porosity of the blood (unitless), and zcell is the volume of a 
red blood cell (L/cell) (Eq. 18).  This term represents a glucose sink, as uptake of the 
analyte by cells removes it from the system. 
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                              (18) 
4.3.6.2 Definition of Porosity of Biofouling Layer and Bulk Compartments 
The porosity of the acellular biofouling layer (εlayer) was calculated using the 
specific hydraulic permeability (k) of a fibrin network, which has been reported by Carr, 
et al. to be within the range of 2 to 7 x10-10 cm2 [65].  For a network of randomly oriented 
fibers, the specific hydraulic permeability is calculated with Equations 19 and 20, where 
ε is εlayer for the simplification of the equation description [66]. 
( )( )
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ε
ε ε
=
−
                                                        (19) 
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As the radius of a fibrin strand (rf) is known to be 150 nm, εlayer can be found for 
the range of reported k [67].  For the model, εlayer was chosen to be 0.91 as it represented 
a midpoint of the calculated porosity values.  The porosity of the bulk space, εbulk , was 
set to be 0.55, one minus the volume fraction occupied by the hematocrit (45 % of the 
volume of blood). 
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Figure 9: Schematic representation of diffusion through bulk blood and a layer 
of adsorbed proteins and cells. 
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Table 5: List of all baseline model parameters. Values listed with * in the 
citation column are model assumptions while those listed with ** are calculated 
values with no previous citation. 
Parameter Values Model Parameters 
Biofouling Layer Bulk Blood Citation 
Diffusion 
Coefficient (D) 
(cm2/sec) 
1.87x10-6 3.5x10-6 [58] 
Porosity (ε) 
(unitless) 
0.91 0.55 ** 
Layer Thickness 
(L) (µm) 
75 - [58] 
Michaelis Menten 
Constant (KM) (µM) 
6.13x103 4x103 [28, 68] 
Maximal rate of 
cellular glucose 
uptake (Vmax) 
(µmol/(cell-sec)) 
4.88x10-11 /1.357x10-12 1.357x10-12 [28, 68] 
Permeability of 
biofouling layer 
(Player) (cm/sec) 
5x10-3 - * 
Conversion 
constant                      
(λ) (mol/(mM-sec)) 
2.574x10-14 
 
- [58] 
Cell Volume (zcell) 
(L/cell) 
9.5x10-13 - [58] 
Glucose Sensor 
Radius (a) (cm) 
0.07 - [58] 
Sensor Surface  
Area (A) (cm2) 
0.0058 - [58] 
 
4.3.6.3 Initial and Boundary Conditions 
For the initial condition, it was assumed that the diffusion time in the biofouling 
layer was much shorter than the time scale of simulation.  Therefore, the initial condition 
for the system was a uniform glucose concentration (Co) multiplied by the porosities of 
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each compartment when the sensor is inserted into the blood at t = 0 sec, a plausible 
assumption as there was no other intrinsic source of glucose once a sample of blood was 
taken for an experiment.  The boundary condition at the sensor/layer interface was that 
the flux of glucose diffusion in the biofouling layer times the surface area (A) was equal 
to the rate of glucose uptake by the sensor, Qsensor.  At the interface of the biofouling layer 
and bulk regions, it was assumed that there was no consumption or accumulation of 
glucose, so the concentrations normalized by the porosities and fluxes were continuous 
across the interface.  No flux boundary conditions were assigned to the outer boundary 
condition at the end of the bulk compartment because glucose could not move into or 
out of the boundary at the edge of the beaker, creating an insulating boundary and 
making the flux at the outer boundary equal to zero. 
4.3.6.4 Glucose Uptake Parameters 
Glucose uptake was considered an enzymatically mediated event, and was thus 
modeled using Michaelis-Menten kinetics [58].  These simulations assumed that the 
glucose consuming cells in the biofouling layer were, depending on the scenario, either 
inflammatory cells or erythrocytes while the cells in the bulk were erythrocytes.  Thus 
the Vmax,bulk was set to 1.36x10-12 µmol/(cell-sec), the reported value of maximal glucose 
consumption rate for human erythrocytes, as reported by Yang, et al. [68].  The baseline 
Vmax,layer value used for these calculations was either 4.88x10-11 µmol/(cell-sec) as reported 
by Ahmed, et al. for glucose uptake by human macrophages during inflammation or the 
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erythrocyte value reported by Yang, et al.[28].  The Vmax of the inflammatory cell was 
chosen to be that of a macrophage, but it is worth noting that other leukocytes such as 
lymphocytes and neutrophils, have similar glucose uptake kinetics [69, 70].   
Five computational scenarios (Table 6) were examined to compare the effect of 
glucose consumption by different cell types (inflammatory cell or erythrocyte) within 
the biofouling layer and the bulk blood.  The results of these simulations were then 
compared directly to two experimentally measured normalized sensor signals in whole 
blood from Figure 11 (the maximal decline following addition of the sensor and the 
minimal decline after a glucose addition to show a range of declines) to find which cell 
type had the dominant effect on decreased sensor signals.  To investigate the ability for 
the proteins within the biofouling layer to act alone as a diffusive barrier for glucose 
transport to the sensor surface, the simulation was run with both Vmax,layer and Vmax,bulk set 
to zero, creating an in silico analog to the PPP studies.   
Table 6: Outline of five different computational scenarios for glucose transport 
to an indwelling sensor.  To represent these changes in cell type, the Michaelis-
Menten kinetic values of Vmax and Km were changed accordingly. 
 Biofouling 
Layer Cell 
Type 
Bulk Blood 
Cell Type 
Scenario 1 Macrophage Erythrocyte 
Scenario 2 Macrophage None 
Scenario 3 None Erythrocyte 
Scenario 4 Erythrocyte Erythrocyte 
Scenario 5 Erythrocyte None 
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4.3.6.5 Modeling Biofouling Layer Glucose Depletion Zone Formation 
To investigate the spatial effect of inflammatory cell aggregation and glucose 
consumption on sensor readings, glucose concentration profiles were plotted with 
respect to distance for different values of Vmax,layer.  The maximal glucose uptake rate of 
the cells in the layer (Vmax,layer) was varied amongst four different values: (1) Vmax=0: 
representative of only an acellular protein biofouling layer, (2) Vmax for erythrocytes, (3) 
Vmax for macrophages and (4) twice the Vmax for macrophages.  The last case was 
considered to assess the possible effect of increased cellular accumulation at the sensor 
interface. 
4.3.6.6. Numerical Methods 
Governing partial differential equations in the simulations were discretized into 
a series of ordinary differential equations using the finite difference method.  
Differential equations from all above studies were solved using the differential equation 
solver, ode15s, in MATLAB. 
4.3.7 Scanning Electron Microscopy of Sensor Surface 
The protocol for scanning electron microscopy (SEM) of the sensors was 
modified from Nurdin, et al. [71].  Clean Medtronic MiniMed SofSensors were incubated 
in freshly collected whole blood and PPP treated in the manner described in §4.3.3 for 24 
hours at 37oC.  After the end of the incubation period, the sensor tips were fixed in 1.5% 
glutaraldehyde in PBS for four hours at room temperature.  The samples were subjected 
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to a series of dehydration steps in solutions of ethanol of increasing concentration before 
treatment with tetramethylsilane.  The treated sensor underwent gold sputter coating to 
a thickness of 7 µm before being imaged on a scanning electron microscope (FEI XL30 
SEM-FEG). 
4.4 Results 
4.4.1 Whole Blood, Dilute Blood and PPP Studies 
Figure 10 shows the reproducibility of results from submerging sensors in whole 
blood.  For both trials, signals initially declined upon immersion in whole blood.  
Moreover, when glucose is added to the system, the signal does not maintain a step 
increase like in the pre-calibration immersion in glucose-spiked PBS.  Post-calibration 
steps verified that sensor functionality was maintained throughout the course of the 
immersion.  This anomalous response in whole blood spurred further experiments 
where sensors were immersed in different blood constituents.  
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Figure 10: Sample behavior of Medtronic MiniMed sensors when incubated in 
whole blood. 
Figure 11 shows mean continuous glucose sensor measurements in whole blood 
(blue solid trace), PPP (red solid trace) and dilute blood (black solid trace) derived from 
the same stock of whole blood, as well as discrete glucose concentrations sampled by 
test strips for each (open circles).  After pre-calibration, one sensor was immersed in PPP 
and the other was immersed in whole blood.  Using an ANCOVA, the slope of the initial 
sensor decline in whole blood was found to be statistically significantly different from 
the initial decline in the PPP case.  Doubling the whole blood glucose at 16 hours and 24 
hours caused jumps in sensor signal followed again by signal decays that were also 
statistically significant from their complementary PPP traces.  Even though the 
magnitude of the corresponding test strip glucose concentrations was always lower, it is 
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important to note that the slopes of the signal declines were found to not be statistically 
significant from the corresponding test strip measurements.   
The PPP-immersed sensor behaved essentially as if it was immersed in PBS.  This 
finding suggests that no glucose was being removed from the system in PPP and that 
adsorption of plasma proteins to the sensor surface during whole blood immersion was 
not contributing to the decreased sensor response in whole blood.  Because the only 
difference between PPP and whole blood is the population of cells, the observed 
declines in whole blood sensor signal relative to PPP would be the result of cells within 
the system consuming glucose. 
The sensor in PPP-diluted blood exhibited an intermediate sensor response when 
compared to the whole blood case.  Similar to the sensor in whole blood, the sensor in 
PPP-diluted whole blood exhibited signal declines upon immersion and following 
glucose bolus additions, albeit with slopes significantly less than whole blood for all 
three cases of decline (p<0.05).  These results indicate that the cells in PPP-diluted blood 
were also consuming glucose but to a lesser extent than in whole blood presumably due 
to the effects of dilution, further demonstrating the effects of cellular consumption on 
sensor signal.  These findings were also corroborated by test strip measurements at 
discrete time points.  
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Figure 11: Comparison of mean glucose sensor readings in platelet poor 
plasma (red), whole blood (blue) and dilute blood (black) as a function of time (n=3). 
Sensor readings are corroborated by One Touch readings for each   (-o-).  * indicates 
statistically significant differences in slopes of sensor signals between whole blood 
and PPP incubations (p<0.05). ** indicates statistically significant differences in slopes 
of sensor signals between dilute blood and PPP incubations (p<0.05). *** indicates 
statistically significant differences in slopes of sensor signals between dilute blood 
and whole blood incubations (p<0.05). 
4.4.2 Numerical Modeling 
The dashed lines in Figure 12 display the maximal and minimal fractional 
experimental signal declines as derived from the data in Figure 11, where the sharper 
decline occurred following the initial sensor immersion and the shallower decline 
occurred following an addition of glucose.  The space between them shaded grey is 
meant to represent the range of sensor declines observed when immersed in whole 
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blood.  The solid lines in Figure 12 are simulated fractional declines in sensor signal with 
respect to time for five distinct scenarios of cellular presence around the sensor (Table 6).   
The erythrocyte-only simulations – be they in the bulk (red), in the layer (cyan), 
or both (black) – all underestimate the initial ~60% sensor decline following the sensor 
immersion in whole blood and the ~40% experimental decline post glucose addition.  
However, when the simulations include just adherent macrophages, the simulations lie 
within the range of experimental sensor declines in whole blood.  The simulation with 
adherent macrophages and bulk erythrocytes overestimates both experimental declines.  
These data suggest that adherent macrophages are more likely the primary mitigators of 
the initial sensor decline, and not adherent erythrocytes as originally suggested by 
Klueh et al. [23, 61].    
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Figure 12: Simulated sensor reading as a function of time.  The ordinate is 
represented as the fraction of initial glucose in the system and the abscissa is time in 
hours. The simulation compares five different scenarios against the range of maximal 
and minimal experimental sensor declines in whole blood from Figure 3 (shaded grey 
area bounded by dotted lines) to determine which group of cells contribute most to 
glucose depletion in each case. Scenario 1 (blue line) is represented by the presence of 
macrophages in the layer and erythrocytes in the bulk. Scenario 2 (green line) is 
represented by the presence of only macrophages in the layer and no cells in the bulk. 
Scenario 3 (red line) is represented by the presence of only erythrocytes in the bulk 
with no macrophages in the layer. Scenario 4 (black line) is represented by the 
presence of only erythrocytes in both the bulk and the layer. Scenario 5 (cyan line) is 
represented by the presence of only erythrocytes in the layer and no cells in the bulk. 
The trends in Figure 12 suggest that the cell-embedded biofouling layer may 
result in the formation of a glucose depletion zone adjacent to the sensor surface.  Figure 
13 contains a family of normalized glucose concentration profiles as a function of 
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distance extending from the sensor surface, through a representative 75 µm thick 
biofouling layer.  When erythrocytes exist as the only cell type within the biofouling 
layer (black dot), the radial decrease in glucose concentration relative to the initial 
concentration is imperceptible, with a decrease of 9x10-5 %.  This finding is nearly 
identical to the case where Vmax,layer=0 (red squares), representing an acellular protein 
biofouling layer.  However, when macrophages are the only cell type within the 
biofouling layer and Vmax,layer=Vmax for macrophages (blue dot), glucose concentrations do 
decrease towards the sensor surface, with concentrations dropping by 4% over the 
length scale.  Moreover, a doubling of the macrophage Vmax within the layer, which is 
meant to represent the increased presence of inflammatory cells at the site of 
implantation, increased the magnitude of depletion by causing concentrations to drop 
by 8% over the length scale. 
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Figure 13: Simulated effects of adherent cell aggregation and glucose 
consumption on glucose concentration at the sensor surface as a function of distance. 
Increases in cell presence were modeled as an increase in Vmax,layer within the layer. 
When macrophages are the sole cell type in the adherent layer (blue circle), there is a 
depletion of glucose with respect to distance. This depletion increases as the number 
of macrophages increases, which is denoted by an increase in Vmax,layer to 2 
Vmax,macrophage (blue open circle). When the adherent layer is populated by only 
erythrocytes (black circle), there is close to no radial depletion.  This is similar to the 
acellular case where Vmax,layer=0 (red open squares), indicating only a biofouling 
layer.  Data presented as fractional signal decline. 
Figure 14 displays a simulated fractional decline in sensor signal caused by the 
presence of an acellular protein adsorption layer with respect to time set against 
experimental sensor data from Figure 11 (black dashed line).  Assuming a representative 
fibrin mat porosity of 0.91, the decrease in glucose concentration with respect to time 
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across the protein film was negligible.  Dramatically decreasing the porosity to a 
physically unrealistic value of 0.1 had a more pronounced, but still small temporal effect 
on glucose transport to the sensor (>90% of the original value).  Taken together, these 
results show that the protein film itself does not restrict the transport of glucose to the 
sensor surface. 
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Figure 14: Simulated effects of the acellular biofouling layer as a diffusive 
barrier with respect to time. Data presented as a fractional signal decline. 
4.5 Discussion 
Building on the work of Klueh et al., the current study employed well-stirred 
whole blood as a simple ex vivo living system to approximate the environment in the 
first few hours of sensor implantation when bleeding, hemostasis and the adhesion of 
blood borne cells are dominant events around the sensor surface [23].  The use of whole 
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blood and PPP allowed for the separation of transport effects from metabolic effects 
arising from the accumulation of blood plasma proteins and blood borne cells at the 
sensor surface.   
Trends in sensor values were compared across sensors by converting all sensor 
readouts from current to concentration.  Post-calibration of sensors removed from whole 
blood or PPP as well as periodic glucose sampling taken with glucose test strips ensured 
that changes in sensor readings were an accurate reporting of glucose concentration in 
the surrounding milieu.   
Figure 11 compares glucose readings for sensors immersed in whole blood, PPP, 
and diluted whole blood.  With each addition of glucose into PPP, both the sensor and 
test strip readings registered steady step increases in glucose concentration.  The results 
from the PPP incubation study were corroborated by a numerical simulation showing 
that the biofouling layer had little effect in limiting glucose transport to the sensor with 
respect to time (Fig. 14).  This behavior in PPP was akin to measurements in buffered 
glucose solution, suggesting that the fouling of sensors by blood plasma proteins like 
those seen in the SEM image of Figure 15d was having no effect on the decrease in 
sensor signal.   
In contrast, the sensor and test strip readings in whole blood registered sharp 
increases followed by declines after initial immersion and additions of glucose.  Sensors 
in diluted whole blood exhibited a combination of step increases and signal declines 
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intermediate between that observed for PPP and whole blood.  Clearly exposure to 
blood caused a decrease in blood glucose concentration that did not result from the 
accumulation of blood plasma proteins at the sensor surface or from a failure of the 
sensor to accurately read glucose; rather, these declines arose from a combination of 
sensor equilibration and cellular glucose consumption.  As sensor output could be 
modulated by the concentration of cells within the blood, the role of cellular presence on 
sensor signal is apparent. 
The ratio for erythrocytes to leukocytes in whole blood is roughly 1000:1; and as 
such, the SEM images of the biofouled sensor surface (Fig. 15) showed many more 
erythrocytes than leukocytes, but clearly not three orders of magnitude more [64]. In 
spite of their larger number, erythrocytes do not exhibit substantial metabolic 
requirements on a per cell basis as their net efflux of glucose is roughly that of the net 
influx [64, 72-74].  In contrast, activated immune cells have significant glucose demands 
[35, 36].  Therefore, it is reasonable to infer that accumulation of the more metabolically 
active leukocytes could more significantly affect the glucose concentration measured by 
the sensor.  As Figure 12 demonstrates, the simulation that comprises adherent 
macrophages in the biofouling layer lies within the range of experimentally observed 
sensor declines.  This suggests that inflammatory cells like macrophages, although fewer 
in number than erythrocytes, are the main determinant for a decrease in sensor signal 
with respect to time.  It should be noted however that bulk erythrocytes, due to their 
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sheer number in blood, still consume a significant amount of glucose. However, the 
computational scenarios where only erythrocytes were present all underestimated the 
experimental sensor declines in whole blood.  
10 µm50 µm
5 µm 2 µm
a b
c d
 
Figure 15: (a,b) SEM images of a blood clot on a sensor surface (1000x, 
5000x).(c) SEM images of leukocyte adhesion on the sensor surface (10000x). (d) SEM 
image of protein adsorption layer on the sensor surface (20000x). Figure 15a shows the 
difference between regions covered in protein and cells and the bare sensor surface 
(outlined by dashed line). Note the infiltration of the active sensing region by cells 
and proteins in (b) (sensing region outlined by a dashed line). 
Figure 13 further extends this conclusion by simulating the ability of erythrocytes 
and macrophages to induce a “glucose depletion zone” within the vicinity of the sensor 
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surface.  When erythrocytes exist as the only cell type within the biofouling layer, the 
radial glucose concentration does not appreciably decrease, making it indistinguishable 
from the acellular case.  Through this comparison, it is evident that erythrocytes do not 
create a glucose depletion zone.  However, when macrophages are considered as the 
only cell type in the layer, depletion occurs with the magnitude of depletion increasing 
with increasing cellular presence.  While the macrophage-mediated cases produce 
seemingly modest depletions, it should be noted that the time post-implantation at 
which these radial concentrations were modeled is merely hours after immersion of the 
sensor in whole blood.  In an in vivo setting, this depletion in turn will inhibit the sensor 
from being able to accurately measure a patient’s interstitial glucose.   
Simulations were run to assess if the cellular component of the biofouling layer 
may have imposed some resistance to glucose transport.  This increase in resistance due 
purely to the steric effects was addressed in Figure 14 where the porosity is decreased 
from 0.9 to 0.1.  Even in this case, a steady state value of greater than 90% of the original 
glucose concentration was maintained throughout the length of the simulation.  Such a 
finding suggests that while the presence of cells can confer transport resistance, the 
effects of this resistance are small compared to the consumptive effects seen in Figures 
12 and 13. 
Given the long-standing uncertainty of how the in vivo environment affects 
glucose sensor function, the current study provides a clearer picture of how protein and 
 75 
cell accumulation at the sensor surface affects sensor performance in a living milieu.  
The whole blood, dilute blood and PPP studies in concert with the numerical findings 
suggest that while the sensors accurately measure the glucose that is able to freely 
diffuse to them, glucose consumption by inflammatory cells accumulated at the sensor 
surface consume the analyte before it can reach the sensor, thereby limiting sensing 
capability. 
Finally, the sensors used in this study are specifically intended for insertion into 
subcutaneous tissue for continuous monitoring of interstitial glucose, and were not 
designed for sensing glucose in bulk blood.  That said, these sensors accurately tracked 
accessible glucose in well-stirred whole blood and performed robustly throughout the 
study. 
4.6 Conclusions 
Whole blood, diluted whole blood, and PPP experiments indicated that decreases 
in sensor signal were attributable to the presence of glucose-consuming inflammatory 
cells proximal to the sensor surface.  Moreover, the biofouling layer of adsorbed proteins 
on the sensor surface was shown to have no contribution to sensor signal declines.  
Computer simulations supported the experimental findings by demonstrating the effect 
that an aggregation of adhered cells has on creating a “glucose depletion zone” of 
glucose proximal to the sensor surface.  The results of this body of work demonstrate 
that instead of sensors failing, as is often reported in the literature, that implant-
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associated changes in the local environment are creating a scenario that inhibits 
otherwise functioning sensors from accurately sampling ambient interstitial glucose 
concentrations. 
. 
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Chapter 5. Development of a Novel Biomimetic 
Construct of the In Vivo 3D Cellular Setting around the 
Sensor for the Focused In Vitro Investigation of Early 
Stage Effects of Implantation on Glucose Sensor 
Performance 
5.1 Synopsis 
Building upon the results of Chapter 4, the goal of Chapter 5 is to design, 
characterize and validate a novel benchtop in vitro system that can accurately 
recapitulate previously reported ex vivo results of sensor decline.  To mimic the 
provisional matrix of proteins and inflammatory cells that forms around an implanted 
sensor, a cell-embedded fibrin gel was designed to surround the sensor.  When 
embedded with macrophages, these fibrin gels contributed to sensor signal declines that 
were similar in both shape and magnitude to sensor signal declines when immersed in 
whole blood.  Neither an acellular fibrin gel nor a gel embedded with cells whose 
glucose surface receptors had been blocked provided diffusive barriers to glucose 
transport, showing that the diminished signals from the presence of cell-embedded gels 
were metabolically-mediated.  Additionally, gel constructs exhibited sensitivity to cell 
activation, as those embedded with macrophages that had been activated with both LPS 
and PMA demonstrated larger decreases in sensor signals than sensors surrounded by 
unstimulated macrophages.  A computational model describing glucose transport 
through a cell-embedded fibrin gel was also built to validate the experimental findings 
by calculating the glucose uptake parameters necessary for such experimental declines. 
 78 
5.2 Introduction 
For implantable glucose sensors to be a more reliable and accessible option for 
diabetes management, their useful lives must be extended beyond the period of days 
that is the current standard in the industry.  As all commercially available glucose 
sensors are approved by the FDA for no more than seven days in vivo, a small but 
growing body of literature is focusing on how tissue reactions in that time window 
occurring just days after implantation affect sensor function [75, 76].  Previously, work 
by the author demonstrated the negative impact that early stage inflammatory cell 
aggregation could have on sensor response in a whole blood ex vivo system [75].  Beyond 
creating a diminished signal with respect to time, the previous study demonstrated 
through computational modeling how the presence of a large amount of macrophages 
proximal to the sensor surface could create a “glucose depletion zone” where the 
interstitial concentration of glucose with respect to distance decreases near the sensor 
surface due to cellular glucose consumption. 
Similarly, Klueh, et al. have investigated the potential deleterious effects of 
inflammatory cell aggregation on sensor response in a serious of studies [61, 75-78].  
Using an in vivo murine system, Klueh, et al. have shown that sensors implanted in 
macrophage deficient and macrophage depleted mice demonstrated improved 
performance as compared to those implanted into normal mice [78].  A recent 
publication by the group also demonstrated the effect of macrophage presence on sensor 
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response in vitro.  When simply injected near the sensor surface, macrophages generated 
enough of a consumptive sink to dramatically decrease sensor output relative to a non-
treated sensor [77]. 
While both the work in Chapter 4 and the recent publications by Klueh, et al. are 
significant in elucidating the potential compromising effects of inflammatory cell 
accumulation on sensor response, each comes with caveats.  With respect to the whole 
blood study, the mass of blood present as a result of implantation will be reabsorbed 
and cleared in a period of days in vivo, leaving inflammatory cells and blood borne 
proteins as the only capsular constituents present until the recruitment of fibroblasts and 
the deposition of extracellular matrix.  A more physiologically relevant model of short 
term tissue response should include just the relevant proteins and cells.  With respect to 
Klueh’s in vitro assessment of macrophage presence, macrophages were simply ejected 
on to the sensor surface.  A more complete in vitro model of early stage tissue response 
should incorporate all the relevant features of the provisional matrix in a three 
dimensional construct.  In this way, the in vivo setting is more accurately recapitulated 
for analysis of sensor response. 
In an attempt to build on the previous work in Chapter 4 as well as the recent 
advancements by Klueh, et al., we have developed a novel construct that can mimic the 
in vivo 3D cellular setting around the sensor for the focused in vitro investigation of early 
stage effects of implantation on glucose sensor performance vis-à-vis cellular glucose 
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consumption.  This new in vitro construct is based upon a previously published 
technique for the fabrication of tissue engineered 3D muscle bundles from Bian, et al. 
[79].  This technique presents a number of features that can be used to create 
physiologically accurate, biomimetic surrogates of the provisional matrix surrounding 
an implanted sensor.  First, the construct is comprised of a fibrin gel, making it 
particularly applicable for the study of glucose sensors as fibrin is the primary 
component of the protein biofouling layer that adsorbs onto the sensor surface 
immediately after implantation.  Secondly, it is highly tunable and robust for both cell 
number and type.  These cell-embedded gels have been demonstrated to be able to 
accommodate cellular concentrations over 107 cells/mL for various cell types including 
skeletal muscle, cardiomyocytes, stem cells and epithelial cells [79-82].  Lastly, cells 
within these fibrin gels have been shown maintain viability and functionality over a 
period of weeks post-fabrication [79].   
With these design considerations in mind, we developed macrophage-embedded 
fibrin gels by incorporating a physiologically relevant 3D fibrin substrate with RAW 
264.7 macrophages.  Sensors were then inserted into these gels to examine their effects 
on sensor response.  Results indicate that when inserted into macrophage-embedded 
gels, sensor declines mimic those declines reported in Chapter 4.  Moreover, the sensor 
signal decline was shown to be metabolically regulated, and not an effect of limited 
diffusion of glucose to the sensor surface.  These findings further demonstrate that the 
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environment around the sensor is acting as a sink for glucose, thus preventing the sensor 
from accurately sampling interstitial glucose.  In the future, this well characterized in 
vitro surrogate for the provisional matrix may serve as a screening tool to test how 
different biologically-motivated surface design considerations could impact sensor 
response. 
5.3 Materials and Methods 
5.3.1 Fibrin Gel Fabrication 
The design for the in vitro fibrin gel system is based upon a method developed by 
Bian, et al. for the construction of biomimetic three dimensional muscle tissue 
architectures [79].  Figure 16 outlines the experimental protocol for construction of the 
gels.  The volume of these gels was specified to be 1 mL.  Briefly, they were made by 
combining two solutions: (1) 200 µL bovine plasma fibrinogen (10 mg/mL, Sigma-
Aldrich, St. Louis, MO), 100 µL Matrigel (BD Biosciences, Bedford, MA) and 480 µL of 
cells suspended in media at 4.2x106 cells/mL and (2) 240 µL of 2x cell media and 20 µL 
bovine thrombin (50 U/mL, Sigma-Aldrich, St. Louis, MO).  Once diluted with the other 
reagents, the final cell concentration in the gel was 2x106 cells/mL.  This value was 
chosen as it is representative of the histological density of inflammatory cells 
surrounding an area of inflammation and wound healing, as reported by Sisco, et al. 
[83].  The 2x media and thrombin solution was then pipetted into the cell solution to 
make a 1 mL volume.  Once mixed, the full solution was quickly pipetted into a 
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cylindrical mold and allowed to crosslink for 30 minutes at 37oC.  Before the addition of 
the non-crosslinked fibrin gel solution, each cylindrical mold was pre-treated with 0.2% 
(wt/vol) Pluronic F-127 (Sigma-Aldrich, St. Louis, MO) to prevent adhesion of the 
crosslinked gel to the mold.  After fabrication, the gels were removed from the mold and 
incubated in cell media at 37oC for 24 hours before use.  Cell viability within the gel was 
assessed and confirmed after experiments via fluorescent imaging.  Hoechst 33342 dye, 
applied at a concentration of 1 µL/mL for 30 minutes at 37oC, was used to image all cell 
nuclei.  Calcein AM dye, applied at a concentration of 2 µL/mL for 30 minutes at 37oC, 
was used to image all live cells.  Ethidium homodimer-1, applied at a concentration of 2 
µL/mL for 30 minutes at 37oC, was used to image all dead cells.  All fluorescent reagents 
were purchased through Invitrogen (Eugene, OR). 
 
Figure 16: Outline of Fabrication of Cell-Embedded Fibrin Gels 
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5.3.2 Cell Culture 
Two different cell types were incorporated into the fibrin gels for these studies.  
The first cell type was the RAW 264.7 murine macrophage cell line (ATCC, Manassas, 
VA).  This cell type was chosen as the model inflammatory cell in this study.  The second 
cell type was the 3T3 murine fibroblast/pre-adipocyte cell line and was used as an 
alternate cell type in the subsequent sensor studies to investigate the effects of cell type 
on sensor response.  Both cell types were cultured in low glucose (100 mg/dL) 
Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma Life Sciences, St. Louis, MO) 
supplemented with 10% (v/v) fetal bovine serum (Sigma-Aldrich, St. Louis, MO), 
penicillin (50 U/mL) and streptomycin (100 µg/mL) at 37oC and 5% CO2.   
5.3.3 Functional Sensor Testing with Fibrin Gels 
The sensor used in this study was the same commercially available Medtronic 
Minimed SofSensor used in the studies outlined in Chapter 4.  Similar to the protocols in 
Chapter 4, sensors went through a pre-treatment calibration stage to allow for sensor 
equilibration.  In these instances, each sensor was incubated in low glucose (100 mg/dL) 
DMEM cell media for four hours to allow a steady state, baseline current to form.  As 
sensors were not interrogated with subsequent additions of glucose, a multi-step 
calibration was not performed as in Chapter 4.  Additionally, the findings of Chapter 4 
verified the predictable, linear relationship between sensor current and calibration.  
Once a baseline current had been reached for a given sensor, the sensor probe would be 
 84 
inserted into the top of a cylindrical fibrin gel.  Special care was taken to ensure that the 
whole sensing region of the sensor was surrounded by the gel.  The gel-covered sensor 
was then placed back in the low glucose media and allowed to gather current readings 
for 24 hours.   
To test the capacity of cell-embedded fibrin gels to diminish sensor signals, four 
different cases were initially tested during the treatment phase: (1) treatment with a 
macrophage-embedded gel with a cell concentration of 2x106 cells/mL, (2) treatment 
with a fibroblast-embedded gel with a cell concentration of 2x106 cells/mL, (3) treatment 
with an acellular gel or (4) treatment with no gel on the sensor surface.  Figure 17 
represents the four different cases being tested.  All media in which these cases were 
were well-stirred to avoid the formation of any boundary layers. 
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Figure 17: Outline of functional testing of the effect of fibrin gels on sensor 
performance 
5.3.4 Effects of Inflammatory Activation of Macrophages on Sensor 
Signal 
To more accurately recapitulate the in vivo post-implantation environment 
around the sensor, macrophages were activated to a more inflammatory phenotype 
before being embedded in gels.  Macrophages were stimulated with either LPS (1 
µg/mL, Sigma-Aldrich, St. Louis, MO) for 24 hours or PMA (50 nM, Sigma-Aldrich, St. 
Louis, MO) for 72 hours to activate inflammatory pathways and upregulate extracellular 
glucose uptake prior to gel fabrication.  Stimulation times were based upon previously 
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reported protocols by Schutte, et al. [84].  Additionally, macrophages were stimulated 
with genistein, a naturally occurring isoflavone in soybeans and tyrosine kinase 
inhibitor that has been shown to decrease both inflammatory cytokine production as 
well as extracellular glucose uptake in LPS-stimulated RAW 264.7 macrophages [28, 85-
87].  Macrophages were stimulated with genistein at a concentration of 100 µM for 24 
hours before gel fabrication.  In addition to testing the effects of cell activation, these 
cases further examined whether observed signal declines were a result of cellular 
glucose uptake or steric exclusion of the analyte due to decreased void space in the gel. 
Similar to the protocol in the above section, once a baseline current had been 
reached for a given sensor, the sensor probe would be inserted into the top of a 
cylindrical fibrin gel.  Special care was taken to ensure that the whole sensing region of 
the sensor was surrounded by the gel.  The gel-covered sensor was then placed back in 
the low glucose media and allowed to gather current readings for 24 hours.  All media in 
which these cells were incubated were well-stirred to avoid the formation of any 
boundary layers. 
5.3.5 Statistical Analysis of Experimental Data 
Each case described above was repeated to have a sample size of n=3.  Data 
points were verified for being from a normal distribution using a Jarque-Bera test in 
MATLAB with the command “jbtest” for a value of p<0.05.  This test is preferred over 
other normality tests when comparing datasets of small sample sizes as it minimizes the 
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occurrence of Type I errors.  Data are presented as means ± standard deviation.  A one-
way repeated measures analysis of variance (ANOVA) was conducted to assess 
statistical significant differences amongst treatments (p<0.05) in MATLAB.  Bonferroni’s 
multiple comparison tests at a familywise error rate of 0.05 were then performed for post 
hoc analysis. 
5.3.6 Validation of the In Vitro Fibrin Gel Results through 
Computational Modeling 
To validate the experimental design, a numerical simulation of the experimental 
setup above was derived and implemented using MATLAB.  Figure 18 presents a 
schematic representation of the model used in this study, which was modified from 
models presented in previous articles by the author [58, 75].  Briefly, transport of glucose 
through the environment surrounding the sensor was treated as a two compartment 
construct.  The first compartment, the one closer to the sensor with respect to distance, 
was the gel layer (Cgel), a thin layer of the fibrin based gel and entrapped cells that 
surrounds the sensors during the experiment.  The second compartment (Cmedia) was the 
media surrounding the sensor and gel.  Values for all constants are defined in Table 7.
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Figure 18: Schematic of computational model for the validation of fibrin gel 
results 
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Table 7: List of all baseline model parameters for computational model. Values 
listed with ** are calculated values with no previous citation. 
Parameter Values Model Parameters 
Gel Layer Media Citation 
Diffusion 
Coefficient (D) 
(cm2/sec) 
6.8x10-6 6.8x10-6 [88] 
Porosity (ε) 
(unitless) 
0.975 - ** 
Layer Thickness 
(L) (cm) 
0.43 - ** 
Michaelis Menten 
Constant (KM) (µM) 
6.13x103  [28] 
Maximal rate of 
cellular glucose 
uptake (Vmax) 
(µmol/(cell-sec)) 
4.88x10-11  [28] 
Conversion 
constant                      
(λ) (mol/(mM-sec)) 
2.574x10-14 
 
- [58] 
Cell Volume (zcell) 
(L/cell) 
2.1x10-12 - [89] 
Glucose Sensor 
Radius (a) (cm) 
0.07 - [58] 
Sensor Surface  
Area (A) (cm2) 
0.0058 - [58] 
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The porosity of the fibrin capsule was calculated by finding the percent weight 
difference between a newly made, fully hydrated fibrin gel and fully lyophilized sample.  
The value of 0.975 represents a mean of three samples.  Such a high porosity is similar to 
the calculated porosity of a fibrin biofouling layer (ε=0.91) in Chapter 4. 
5.3.6.1 Governing Equations 
The governing equation describing glucose concentration in the gel layer (Cgel) is 
a non-linear, uni-dimensional diffusion-reaction equation in cylindrical coordinates 
through a porous medium. It has a diffusion term and a sink term to describe uptake by 
adherent cells (Eq. 21)  
( , ) ( , )
( , )
gel gel gel
gel
C r t D C r t
r Q r t
t r r r
 ∂ ∂∂  = −  ∂ ∂ ∂ 
                         (21) 
Qgel is defined as the rate of glucose uptake by cells in the layer and is modeled 
by Michaelis-Menten kinetics, where Vmax,gel is the maximum rate of consumption 
(µmol/(cell-sec)), KM,gel is the Michaelis-Menten constant (µmol/ L), εgel is the porosity of 
the gel layer (unitless), and zcell is the volume of a macrophage within the gel layer 
(L/cell) (Eq. 22).  Michaelis-Menten formalism was chosen because the process of 
facilitative transport via the uptake of glucose through GLUT-1 and GLUT-3 
transporters in RAW 264.7 macrophages fit this model well in previous literature studies 
[28, 70].  In this model, the fibrin network and cells were assumed to be well mixed 
within the gel layer.  Therefore, they were not considered separately. 
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The governing equation for glucose concentration in the media (Cmedia) is a non-
linear, uni-dimensional diffusion-reaction equation in cylindrical coordinates through a 
porous medium (Eq. 23).  As there are no cells in the media layer, there are no 
consumptive terms in the equation. 
( , ) ( , )media media mediaC r t D C r tr
t r r r
 ∂ ∂∂ =   ∂ ∂ ∂
                              (23) 
5.3.6.2 Initial and Boundary Conditions 
For the initial condition, it was assumed that the diffusion time in the gel layer 
was much shorter than the time scale of simulation.  Therefore, the initial condition for 
the system was a uniform glucose concentration (Co) multiplied by the porosity of the 
gel compartment when the sensor is inserted into the media at t = 0 sec, a plausible 
assumption as there was no other intrinsic source of glucose once an experiment began.  
The boundary condition at the sensor/layer interface was that the flux of glucose 
diffusion in the gel layer times the surface area (A) was equal to the rate of glucose 
uptake by the sensor, Qsensor.  At the interface of the gel layer and media regions, it was 
assumed that there was no consumption or accumulation of glucose, so the 
concentrations normalized by the porosities and fluxes were continuous across the 
interface.  No flux boundary conditions were assigned to the outer boundary condition 
at the end of the media compartment because glucose could not move into or out of the 
 92 
boundary at the edge of the beaker, creating an insulating boundary and making the 
flux at the outer boundary equal to zero. 
5.3.6.3 Utilizing Computational Modeling for Nonlinear Curve Fitting of 
Experimental Data 
The goal of this computational model is to determine the glucose uptake 
parameters necessary to recreate experimental findings of sensor decline in the presence 
of cell-embedded gels.  Qgel is the only component with consumptive terms in the model 
and within that term, both the porosity of the gel and volume of a cell are assumed to be 
fixed in the experiment.  Therefore, changes in the output of the model were dependent 
on only two terms, Vmax,gel, the maximum rate of consumption of the cells within the gel 
(µmol/(cell-sec)) and KM,gel ,the Michaelis-Menten constant for the cells within the gel 
(µmol/ L).  The computational model described above was thus automated to run using 
every possible combination of 20 different values of Vmax,gel and 20 different values of 
KM,gel, all of which centered around reported values of Vmax (4.88x10-11 µmol/(cell-sec), 
noted as Vmax,o) and KM (6.13x103 µM, noted as KM,o) for RAW 264.7 macrophages at 37oC 
[28].  The output from each run of the model was the trace of the normalized glucose 
current as a function of time at the sensor surface, giving 400 different traces to be 
analyzed for a goodness of fit.  Simulations were run for a timescale of 5 hours and 
compared to the first five hours of the experimental data.  This modification was made 
because the computational model assumes that macrophages will continue to consume 
glucose as an endless sink.  In reality though, analyte consumption will reach a maximal 
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level within the cell.  It was assumed that during the first five hours that cells in the 
experiment would consume glucose before reaching a level of internal saturation.  As 
the sensor was presupposed in this model to be perfectly efficient, the trace at the sensor 
surface was assumed to be the amount of glucose converted into current by the sensor. 
Each of the 400 modeled declines in normalized sensor current was then 
compared to the experimental traces of sensor decline in the following three cases:  (1) 
presence of an unstimulated macrophage-embedded gel, (2) presence of an LPS-
stimulated macrophage-embedded gel, and (3) presence of a PMA-stimulated 
macrophage-embedded gel.  The genistein case was not considered as it was meant to 
serve only as a negative control that demonstrated how the decline in signal was 
metabolically regulated.  To determine the best modeled fits of the experimental data, 
coefficients of determination (R2) were calculated to find the best fit for the three 
experimental conditions as one minus the residual sum of squares divided by the total 
sum of squares.  Comparison of R2 values was chosen for analysis at this metric 
quantifies how well a model describes the experimental data.  Figure 19 outlines the 
flowchart to determine the best modeled fit of the experimental data. 
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Figure 19: Computational flowchart to determine which glucose uptake 
parameters(Vmax,gel and KM,gel) best fit the experimental data when put into the model 
in this section.  The above figure is generalized for four inputs of Vmax and two of KM. 
5.3.7 Fluorescent Imaging of Glucose Uptake 
To complement the data detailing the effect of cellular presence on sensor 
readings, fluorescent images of cellular glucose uptake were taken for each of the 
macrophage activation cases described above.  The fluorescent glucose analog, 2-[N-(7-
nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-D-glucose (2-NBDG) (Life 
Technologies, Eugene, OR), was used as the fluorescent tracer to image the uptake of the 
analyte.  Unstimulated, LPS-stimulated (1 µg/mL for 24 hours), PMA-stimulated (50nM 
for 72 hours) and genistein-stimulated (100 µM for 24 hours) RAW 264.7 macrophages 
were seeded in different wells of a 24 well plate at a concentration of 105 cells/well in 1 
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mL low glucose DMEM (100 mg/dL) supplemented with 10% (v/v) fetal bovine serum 
(Sigma-Aldrich, St. Louis, MO), penicillin (50 U/mL) and streptomycin (100 µg/mL). 
After 24 hours in the wells, the cell culture media in each well was aspirated and 
replaced with fresh low glucose DMEM supplemented with 100 µM 2-NBDG.  This 
value has been previously reported as the optimal concentration for imaging of the 
tracer [90-92].  The 2-NBDG treated cells were then incubated for 30 minutes at 37oC.  
After incubation, the 2-NBDG-supplemented media was aspirated and each well was 
washed three times with sterile PBS to remove any potential background fluorescence in 
imaging.  Fluorescent images were captured with a Nikon TE2000U microscope and NIS 
Elements software (Nikon) at a fixed exposure time to allow for qualitative comparisons 
across treatments.  Images were post-processed in ImageJ. 
5.4 Results 
5.4.1 Assessing Cellular Viability and Distribution within the Gel 
Construct 
To ensure cellular viability during both the fabrication of the gel as well as the 
experiments with glucose sensors, live/dead staining was performed in both cases.  
Figure 20 shows representative images of each case 
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Figure 20: (a) Live/Dead assay of a cell-embedded fibrin gel 24 hours after 
fabrication (4x). (b) Live/Dead assay of a cell-embedded fibrin gel immediately 
following a 24 hour experiment when surrounding a glucose sensor (10x).  Live cells 
are stained green, dead cells are stained red and all nuclei are stained blue. 
From the staining in Figure 20a, it can be seen that process of fabricating these 
cell-embedded gels did not affect viability.  Similarly, following 24 hour experiments, 
viability remained high, with few dead cells present in the image (Figure 20b). 
Beyond the issue of viability, distribution of the cells within the gel was also of 
importance.  A desirable gel should have a uniform distribution of cells throughout the 
gel so as to ensure that an equal amount of cells were present along the length of the 
sensor.  This consideration ensures a uniform barrier to analyte transport to the sensor, 
negating any spatial heterogeneities in glucose consumption.  Figure 21 shows an image 
of the distribution of live cells on the surface of a cell-embedded fibrin gel.   
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Figure 21: Live cell Calcein AM of distribution of cells on the surface of a cell-
embedded fibrin gel (4x). 
From the image above, it appears that cells are uniformly distributed throughout 
the gel, ensuring a uniform barrier to glucose transport along the length of the glucose 
sensor.   
5.4.2 Assessing Sensor Performance in the Presence of Cell-
Embedded Fibrin Gels 
Glucose sensor response was assessed in the presence of four different 
treatments: (1) treatment with a macrophage-embedded gel with a cell concentration of 
2x106 cells/mL, (2) treatment with a fibroblast-embedded gel with a cell concentration of 
2x106 cells/mL, (3) treatment with an acellular gel or (4) treatment with no gel on the 
sensor surface (Figure 22).  The data are presented as the mean of currents reported by 
the sensor divided by the steady state equilibration value of each sensor before 
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application of the gel on the sensor surface.  Data were normalized for each run of the 
experiment to the respective baseline value because output currents of Medtronic 
Minimed sensors were not consistent from sensor to sensor in solutions with the same 
glucose concentration.  This normalization therefore controlled for sensor-to-sensor 
variability and allowed for multiple traces to be plotted on one graph.  For the ease of 
presentation, only the traces that were not statistically significant (p<0.05) from one 
another are labeled.  Otherwise, it should be assumed that different treatments had 
statistically significant effects on sensor response. 
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Figure 22: The effect of the presence of cell-embedded fibrin gels on glucose 
sensor performance.  Data represented as mean normalized glucose sensor currents 
(n=3) ± standard deviation.  * represents treatments that were not statistically 
significantly different from one another (p<0.05). 
As expected, the bare sensor maintained its baseline signal during the treatment 
phase.  Its reading in low glucose media never deviated to less than 90% of the baseline 
value.  The small decrease in signal that did occur over that time could be attributable to 
consumption of glucose by the sensor itself.  Sensor signals in the acellular gel case 
mimicked those of the bare sensor readings, indicating that the gel itself posed no 
barrier to glucose transport to the sensor surface.  Both cellular gel traces (fibroblast and 
macrophage) were significantly different than the acellular gel and bare sensor cases, 
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elucidating the effect of cellular presence on sensor signal.  Moreover, cell type was 
shown to have an effect on sensor signal, as the macrophage gel signal decreased more 
rapidly than the fibroblast signal.   
5.4.3 Assessing the Effect of Macrophage Stimulation on Sensor 
Performance 
Once the presence of cells was shown to contribute to sensor decline, the gel 
construct was modified to incorporate macrophages activated with both LPS and PMA, 
as their phenotypes more resemble those of macrophages during the in vivo 
inflammatory response to implantation.  The effect of macrophage activation on sensor 
signal is shown in Figure 23. 
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Figure 23: The effect of the presence of macrophage stimulation on glucose 
sensor performance.  Data represented as mean normalized glucose sensor currents 
(n=3) ± standard deviation.  * represents treatments that were not statistically 
significantly different from one another (p<0.05). 
While the activation cases (PMA and LPS-stimulated gels) were not significant 
from one another, each was statistically different from the unstimulated macrophage 
case.  The unstimulated, LPS-stimulated and PMA-stimulated gels were all statistically 
significant from the genistein-treated gel, which served as the negative treatment control 
for this experiment. 
 102 
5.4.4 Comparison of Sensor Responses for Fibrin Gel System and 
Whole Blood System 
In order to determine if the signal decreases seen in Figures 22 and 23 were 
physiologically relevant, they were compared to ex vivo sensor declines previously 
published by the author and collaborators [75].  Figure 24 compares sensor signals from 
both an unstimulated macrophage embedded gel and an LPS-stimulated macrophage 
embedded gel to signal declines in whole blood.   
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Figure 24: Comparison of sensor declines in whole blood to declines in the 
presence of macrophage-embedded fibrin gels. 
Both the unstimulated and LPS-stimulated declines lie within the envelope of 
maximal and minimal sensor declines in whole blood.  While these comparisons are 
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made through five hours and not the 24 hours displayed in the above figures, these 
whole blood data are still instructive to show that the declines in the fibrin gel case are 
comparable to those in the whole blood ex vivo case.  
5.4.5 Validation of Fibrin Gel Results through Computational 
Modeling 
To validate the experimental results presented above, a computational model 
was run to find the metabolic parameters necessary to produce such declines.  Figure 25 
presents each experimental case as well as its corresponding line of best fit for the 
unstimulated, LPS-stimulated and PMA-stimulated macrophage cases shown in Figure 
23.   
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Figure 25: The computational best fit for cases where (a) a PMA-stimulated 
macrophage gel, (b) an LPS-stimulated macrophage gel and (c) an unstimulated 
macrophage gel surrounded a sensor. 
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Overall, modeled outcomes were found to be far more sensitive to changes in 
Vmax than changes in KM.  The metabolic parameters of Vmax and KM necessary to produce 
the best fit for the unstimulated macrophage trace were within 15% and 75%, 
respectively, of the values reported by Ahmed, et al. for RAW 264.7 macrophages [28].  
This proximity to literature values shows that the metabolic behavior of macrophages 
within the 3D gel construct is similar to their behavior in 2D monolayer.  Additionally, 
the best fits of stimulated macrophages produced expected trends where the Vmax values 
of LPS-stimulated (2.2Vmax,o) and PMA-stimulated (6.8Vmax,o) macrophage cases were 
elevated in comparison to the unstimulated case, which is in accord with physiological 
findings detailing the increased capacity for glucose found in activated macrophages 
[28, 70]. 
5.4.6 Fluorescent Imaging of Glucose Uptake 
To visualize the differences in glucose consumption between the different cases 
of stimulation, each case of macrophage stimulation was dosed with the metabolizable 
glucose analog, 2-NBDG at 100 µM, and imaged 30 minutes after administration.  All 
images were captured at the optimal exposure time for the PMA-treated cells, as those 
had the brightest overall signal, to allow for qualitative comparison across treatments.  
Qualitatively, the intensity of the intracellular glucose signal in each case correlates well 
with the glucose consumption observed in Figure 23.  As would be predicted from the 
sensor signal traces immediately after treatment, both PMA-treated and LPS-treated 
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cells had brighter fluorescent signals than the unstimulated macrophage case, with the 
PMA-trace showing the brightest overall signal.  Genistein-stimulated macrophages did 
not have much of a signal, showing that the negative control treatment worked in 
limiting cellular glucose uptake. 
100 µm 100 µm
100 µm100 µm
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Figure 26:  Fluorescent images of 100 µM 2-NBDG uptake 30 minutes after 
administration for (a) PMA-stimulated macrophages, (b) LPS-stimulated 
macrophages, (c) unstimulated macrophages and (d) genistein-stimulated 
macrophages. 
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5.5 Discussion 
From a clinical perspective, the current utility of implantable glucose sensors for 
management of diabetes has been extremely limited due to their abbreviated useful lives 
in vivo.  Indeed, the three to seven day window for which these devices are approved by 
the FDA only allows for continuous glucose monitoring as a feasible diabetes 
management strategy for those who require the most diligent of glucose observation.  
Functionally speaking, sensor behavior during this period would best be considered as 
anomalous and erratic, further limiting sensor efficacy even during the FDA-approved 
time window. 
Beyond being a time scale for clinical approval, the three to seven day time 
window coincides with a period of highly pronounced implant-associated inflammation 
to the newly installed sensor, punctuated by the infiltration and interrogation of the 
sensor surface by inflammatory neutrophils and macrophages [14].  A growing amount 
of evidence in recent literature has pointed to the consumptive capacity of these 
inflammatory cells as a potential barrier to short term sensor accuracy [75-78].  To 
further investigate the causal link between inflammatory tissue reaction and sensor 
function, an in vitro biomimetic surrogate for the provisional matrix of proteins and 
inflammatory cells was fabricated. 
The design specifications for this biomimetic surrogate were chosen to maximize 
its physiological relevance in recapitulating early stage tissue response to an implanted 
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sensor.  First, this construct was composed of a fibrin gel.  The formation of a fibrin 
network immediately surrounding the sensor is one of the major products of the 
coagulation cascade that is triggered upon insertion of the sensor into tissue and is a 
hallmark of the inflammatory response to sensor implantation [93-97].  Secondly, the gel 
constructs were embedded with an inflammatory cell type at a physiologically relevant 
density to recreate the inflammatory cell presence around the sensor.  The RAW 264.7 
murine macrophage was chosen as the candidate inflammatory cell type for the gel 
constructs as it is a ubiquitous cell type for biocompatibility and inflammatory studies in 
the literature and it responds appropriately to inflammatory activation [98-102].  The 
density of cells within the gel was based upon in vivo histology data of macrophage 
infiltration into areas of inflammation and was also within the range of 105 to 107 
cells/mL used by Klueh, et al. for macrophage studies [77, 83].  Lastly, this construct has 
been shown to not negatively impact cell viability or functionality across a wide range of 
cell types. 
Yet, as this construct has yet to be employed for embedding macrophages, cell 
viability had to be assessed before using the gels in an experiment with glucose sensors.  
Figure 20 shows fluorescent live/dead staining for macrophages embedded in a fibrin 
gel.  Both following the fabrication of the gel and the completion of an experiment using 
the gel, viability remained high.  Additionally, the cells within the gel maintained a 
uniform distribution through the gel, as evidenced by the image in Figure 21.  This 
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consideration ensured that there would be an even barrier and resistance to analyte 
transport along the length of the active sensing region of the sensor.  Such an even layer 
of inflammatory cells on the surface aligns well with in vivo histology images where a 
sensor is interrogated along its whole surface by macrophages [17]. 
As a first proof of concept that cell-embedded gels would decrease sensor 
response when surrounding a sensor, glucose sensors were tested in four different cases 
(Figure 22): (1) treatment with a macrophage-embedded gel with a cell concentration of 
2x106 cells/mL, (2) treatment with a fibroblast-embedded gel with a cell concentration of 
2x106 cells/mL, (3) treatment with an acellular gel or (4) treatment with no gel on the 
sensor surface.  Fibroblasts served as the negative cellular control to ensure that any 
declines in sensor signal were not just in response to a bulk presence of cells, but instead 
were specific for cell type.  The bare sensor case served as a control to examine if 
consumption of glucose by the sensor itself was a contributing factor to signal decrease.  
The acellular gel treatment served to examine if the gel itself was serving as a diffusion 
barrier to glucose transport to the sensor surface.  Since there were no cells in these gels, 
the protocol was modified such that 480 µL of cell media was added to the gel 
formulation instead of a cellular solution of media.   
Though the signal did decrease over the period of 24 hours in the bare sensor 
case, the signal never dropped below 90% of its pre-treatment baseline output signal.  
This effect could be due to consumption of the analyte by the sensor itself and is 
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negligible in comparison to the drops observed by sensors surrounded by cell-
embedded gels.  When inserted into acellular gels, sensors maintained signals that were 
redolent of a bare sensor in media.  Indeed, the acellular gel case and the bare sensor 
case were not statistically significant from one another (p<0.05), making it the only case 
comparison in Figure 22 that was not statistically significantly different.  From these 
data, it can be concluded that the gel itself does not provide any diffusive barrier to 
glucose transport to the sensor.  This finding is not surprising given that greater than 
97% of the gel is void space, which is comparable to the 91% void space calculated for a 
fibrin biofouling layer in Chapter 4.  Additionally, the results of this case show that the 
gel does not have a deleterious impact on the enzyme activity of the sensor. 
The presence of cell-embedded gels did have an impact on sensor signal in both 
the fibroblast and macrophage-embedded cases in Figure 22, causing declines to 50% 
and 30% of their respective original signals.  Both cases were statistically significantly 
different from the bare sensor and acellular cases.  Beyond the presence of cells, the 
presence of cell type also affected the sensor signal, as the macrophage-embedded gel 
case produced a significantly lower signal over the length of the experiment than the 
fibroblast-embedded case.  This result was expected as pre-adipocyte fibroblasts do have 
a lower reported Vmax (1.67x10-12 µmol/(cell-sec)) than macrophages (4.88x10-11 
µmol/(cell-sec)) on a per-cell basis at 37oC, thereby providing a useful verification that 
the gel construct would also be sensitive to changes in cell type [28, 49, 103].   
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After the initial verification that cells could reliably maintain viability and 
produce a drop in signal that is sensitive to cell type, a more extensive study was 
conducted using activated macrophages.  Four gel cases were employed in this study: 
(1) treatment with gels embedded with LPS-stimulated macrophages, (2) treatment with 
gels embedded with PMA-stimulated macrophages, (3) treatment with gels embedded 
with unstimulated macrophages and (4) treatment with gels embedded with geinstein-
stimulated macrophages (Figure 23).  The purposes of this study were twofold.  First, 
these treatments served as verification that the observed decrease in signal was 
metabolically regulated instead of a case where the presence of cells in the void space of 
the sensor retarded glucose diffusion to the sensor via steric exclusion.  Secondly, 
activated macrophages present a more physiologically correct model for macrophage 
phenotype and behavior within the site of implantation.  Therefore, to provide a more 
complete in vitro model of sensor behavior, the effect of cell activation had to be 
considered. 
As the negative control treatment, the genistein-treated case produced modest 
declines in signal, dropping only ~20% for the length of the experiment.  This result is 
expected as genistein has been shown to be a competitive inhibitor of glucose uptake, 
decreasing the efficacy of two predominant facilitative glucose transporters, GLUT-1 
and GLUT-3 to extracellular glucose across cell types [28, 104, 105].  Additionally, this 
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case displays that uptake of the analyte is mediated through facilitative diffusion and 
not passive diffusion through the cell membrane. 
Macrophage activation through both LPS and PMA stimulation was shown to 
have an effect on sensor signal relative to both the unstimulated macrophage case and 
the genistein-stimulated macrophage case.  However, the stimulated cases did not differ 
significantly from one another.  Given the considerable metabolic demands that 
activated macrophages face during the foreign body response in the way of attempted 
phagocytosis, respiratory burst, cytokine production and cellular recruitment, it is 
plausible that these treatments would increase the uptake of glucose.  Treatment with 
each activator has been shown to increase cell surface transporter affinities for 
extracellular glucose in macrophages, effectively raising the maximal rate of glucose 
uptake [36, 42, 43]. 
Qualitatively, the trends seen in Figure 23 can be confirmed with the images in 
Figure 26, which presents uptake of a fluorescent analog of glucose, 2-NBDG, in each of 
the four cases detailed above.  2-NBDG served as an ideal analog for glucose as its 
uptake has been shown to be facilitated through the same major transporters as glucose, 
thus providing an accurate basis for comparison [91].  As it is decomposed into a non-
fluorescent constituent, the optimal staining time is a dynamic equilibrium between 
uptake and decomposition.  For this cell type, the optimal staining time was determined 
to be 30 minutes for a 2-NBDG dose of 100 µM.  The short time of incubation also 
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avoided the possibility of the fluorescent signal quenching with increased exposure to 
the tracer.  At this time, the effects of activation on uptake are clear, as the intensities in 
both the LPS and PMA-stimulated cases are brighter than the unstimulated and 
genistein-stimulated traces just by inspection.  The PMA-stimulated traces are brightest 
on a per-cell basis, which is consistent with the trends seen in the first 30 minutes of 
Figure 23.  Predictably, the fluorescent signals in the genistein-stimulated case are faint 
and barely perceptible over the background, which is expected given that genistein is 
known to decrease GLUT transporter affinity to the analyte. 
To add context to the results of the in vitro cell-embedded gel design, the 
unstimulated and LPS-stimulated macrophage cases were compared to the maximal and 
minimal ex vivo results for sensor decline presented in Chapter 4 (Figure 24).  As the 
figure shows, both traces lie within the envelope outlined by the maximal and minimal 
ex vivo declines, demonstrating that the effects seen with the in vitro gel system are 
adequate representations of what would occur in a more realistic, clinical setting.  
Moreover, the magnitudes of decline seen in these cases are very similar to those 
reported in both in vitro and in vivo studies by Klueh, et al. for comparable (~24 hour) 
time frames [77].  In their in vitro studies, the group witnessed sensor declines to 
between approximately 20% and 35% of the pre-treatment signals over 24 hours.  
Similarly during in vivo studies where 2.5x106 macrophages were injected at the site of 
implantation in a mouse, signals declined in the same fashion over the period of 24 
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hours.  Favorable comparisons between the results of Figure 24 and previously 
published reports of sensor decline in the presence of inflammatory cells demonstrate 
the utility that this construct could have as an in vitro screening tool for sensor 
biocompatibility. 
As an additional validation of the fibrin gel design, a computational model of the 
experimental setup was designed and implemented to quantify the metabolic 
parameters necessary to produce the experimental declines seen in Figure 23.  The major 
consideration in performing such a validation was due to the behavior of the cells once 
cultured in a 3D environment.  Metabolic characteristics for macrophages, even RAW 
264.7 macrophages in particular, are well characterized for a number of different 
conditions, including variations in temperature and treatment type [36, 42-44].  
However, all of these studies have been based on macrophages cultured in a 2D 
monolayer on a substrate like tissue culture polystyrene that has been optimized for cell 
culture.  When cell culture is moved from a 2D monolayer to a 3D construct like the 
fibrin gel presented above, a number of complex factors, from the physical forces on the 
cells themselves to the interaction between the cells and the surrounding 
microenvironment can alter cell phenotype and potentially negatively impact their 
functional capabilities relative to a 2D monolayer [106, 107].  Therefore, this model was 
implemented both to test whether the Vmax and KM values necessary to recreate the 
results from Figure 23 were reasonable relative to published literature values and to 
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determine whether changes in trends across treatments aligned with previously 
reported results.   
Best fits were determined through a screening process where modeled results 
were compared to experimental traces through comparison of R2 values.  The best fits 
described the variations in the observed experimental data well, with R2 values ranging 
from 0.845 in the unstimulated macrophage case to 0.989 in the PMA-stimulated 
macrophage case.  The best fit for unstimulated macrophage case was found to have a 
Vmax of 1.15Vmax,o and a KM of 1.75KM,o.  These results agree well with the benchmark 
values of each reported by Ahmed, et al. and demonstrate that encapsulation within the 
3D fibrin gel substrate does not adversely affect cell function with respect to glucose 
uptake [28].   
Likewise, best fits of traces from activation of macrophages with LPS and PMA 
resulted in increased consumptive parameters in each case.  The best fit of the PMA-
stimulated macrophage case had a Vmax of 6.8Vmax,o and a KM of 3.7KM,o.  While there is 
not a direct comparison of fold increase in Vmax and KM from PMA-stimulated RAW 
264.7 macrophages, Kiyotaki, et al. reported a two-fold increase in the Vmax of J774 
murine macrophages after only 3 minutes of PMA incubation at a concentration of 6 
µg/mL when compared to unstimulated macrophages [35].  Ahmed, et al. reported a 4 
fold increase in glucose transporter affinity to glucose when RAW 264.7 macrophages 
were cultured with PMA for 30 minutes [28].  The best fit of the LPS-stimulated 
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macrophage case had a Vmax of 2.2Vmax,o and a KM of 2.5KM,o.  These results agree well 
with the findings of both Gamelli, et al. and Fukuzumi, et al., who observed two to 
three-fold increases in maximal glucose consumption rate in macrophages stimulated 
with LPS [42, 43].  Overall, the increases in Vmax calculated from the stimulated cases 
make sense from a physical perspective.  With an increased demand for the analyte 
during inflammatory stimulation, cells would be expected to increase their rate of 
consumption to meet such metabolic demands.  While it should be noted that the model 
was more sensitive to changes in Vmax than KM, it was nonetheless surprising that 
stimulation was met with increases in KM.  Increases in KM suggest that the transporters 
are becoming less effective in their analyte uptake.  For cases of inflammatory 
stimulation, one would think that KM would decrease, as that is representative of an 
increase in transporter affinity to the analyte.  Despite these decreases in the affinity 
with which the cells are taking up the analyte, their rate of maximal consumption on a 
per-cell basis is increased, which over time will translate to higher consumption in the 
provisional matrix.  Taken in concert, these stimulated case model fits further 
demonstrate the utility of the fibrin gel construct by showing that stimulated cells in a 
3D environment have similar increased glucose uptake profiles to stimulated cells in a 
2D environment. 
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5.6 Conclusions 
In this study, a biomimetic surrogate of early stage tissue reaction to 
implantation was fabricated and used as a tool to assess glucose sensor performance in 
the presence of pro-inflammatory macrophages proximal to the sensor surface.  When 
inserted into macrophage-embedded fibrin gels, sensors produced declines over 24 
hours that were comparable to previous ex vivo and in vivo studies with glucose uptake 
parameters that were similar to those reported in the literature.  Additionally, the 
versatility of the design was demonstrated as gel constructs were shown to be 
responsive to cellular stimulation, as sensors inserted into both LPS and PMA-
stimulated macrophage gels produced significant drops in signal relative to the 
unstimulated macrophage case.  As the causal link between tissue reaction and sensor 
function continues to be clarified, this in vitro fibrin gel system presents an exciting and 
promising platform for assessing early stage sensor function without the need for 
immediate in vivo studies. 
.
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Chapter 6. Dissertation Overview and Future Directions 
6.1 Dissertation Overview 
The global hypothesis motivating this research is that implant-associated tissue 
reactions negatively impact in vivo glucose sensor performance.  As the nature and 
extent of tissue reaction to sensor implantation changes over time, this research tackled 
the global issue of tissue reaction by examining two distinct temporal regimes of the 
overall process.  The first regime examined late stage (weeks to months) interactions of a 
sensor with fully formed capsular tissue and served as the focus of Chapter 3.  The 
second regime examined the ways in which early stage (days to weeks) acute 
inflammatory tissue reaction to sensor implantation could negatively impact sensor 
response, and served as the focus of Chapter 4.  Building upon these results, the 
information in Chapter 5 presented a novel in vitro platform for recreating such acute 
inflammatory tissue around a sensor as a potential screening method for 
biocompatibility of future sensor designs. 
With respect to late stage interaction, if a sensor signal is able to persist for weeks 
after implantation, its performance will be characterized by both high attenuation of the 
signal as well as a long lag time relative peak blood glucose readings.  However, it is 
unknown which aspects of the foreign body capsule have the most pronounced effects 
in causing both signal attenuation and signal lag.  Due to the well-characterized 
constituents, geometry and orientation of fully formed capsular tissue, a computational 
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model of glucose transport out of the capillaries, and through both the interstitial space 
in the subcutaneous tissue and fully formed capsular tissue to a functioning sensor was 
constructed.  This model of glucose transport was able to recreate in vivo results for lag 
and attenuation with physiologically accurate parameters taken from literature.  Using 
logarithmic sensitivity analysis, the sensitivities of signal attenuation and lag to five 
different parameters, (1) capsule diffusion coefficient, (2) capsule porosity, (3) vessel 
density, (4) maximal cellular glucose consumption rate in the capsule, and (5) capsule 
thickness, were calculated.  Sensor signal lag was most sensitive to capsule thickness, 
demonstrating that lag is determined not by the contributions of the inner constituents 
of the capsule but by the macro length scale of the dense, avascular collagen capsule.  
Sensor signal attenuation was most sensitive to subcutaneous vessel density and capsule 
porosity proximal to the sensor.  This finding was expected since vessels are the only 
source of glucose in the system. As a result, a decrease in the amount of glucose present 
will produce a concomitant decrease in the glucose to be measured relative to blood 
glucose values.  Additionally, as the capsule becomes less porous, there are fewer 
pathways for glucose to traverse to get to the sensor, resulting in an accumulation of 
glucose within the foreign body capsule.  Moreover, when the variations in parameters 
were analyzed to examine what aspects will produce an ideal situation of low signal lag 
and low signal attenuation, subcutaneous vessel density was identified as being the 
largest determinant for such a scenario. 
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Early stage sensor response to implantation is generally marked by erratic and 
anomalous signals that frequently drop quickly and obscure accurate glucose readings 
in the first days and weeks following implantation.  As compared to late stage tissue 
reactions composed of a dense, avascular capsule, early stage tissue reactions are 
mediated by two processes: blood borne protein adsorption and inflammatory cell 
adhesion on the sensor surface.  The goal of Chapter 4 was to elucidate the effects of 
these two processes on sensor response using an ex vivo whole blood system. 
When incubated in whole blood, sensors reported a marked decrease in signal.  
However, when incubated in platelet poor plasma, the fraction of blood containing only 
protein and small molecules, the sensor signal maintained a steady state despite the 
adsorption of proteins onto the sensor surface.  The platelet poor plasma trace, coupled 
with modeled results of glucose traveling through an acellular protein mat, demonstrate 
that protein adsorption is not the culprit in the anomalous and erratic sensor behavior 
seen immediately following implantation.  As the only difference between whole blood 
and platelet poor plasma is the presence of cells, it could be assumed that cells within 
the blood were behaving as a glucose sink and consuming the analyte before it could 
reach the sensor.  Moreover, computational models comparing the transport of glucose 
from a bulk blood phase through the provisional matrix of cells and protein found that 
the observed ex vivo decreases were a result of glucose consumption by inflammatory 
macrophages, not erythrocytes.  Models also demonstrated how glucose consumption 
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by macrophages can induce a “depletion zone” of glucose with respect to distance from 
the sensor.  As a result, otherwise functioning sensors are not able to sample more 
representative traces of interstitial glucose.   
Buoyed by the work of Chapter 4 as well as the subsequent findings of Klueh, et 
al., Chapter 5 focused upon the design and validation of a novel construct that can 
mimic the in vivo 3D cellular setting around the sensor for the focused in vitro 
investigation of early stage effects of implantation [76-78].  The design was comprised of 
a physiologically relevant 3D fibrin gel substrate embedded with a RAW 264.7 murine 
macrophage cell line.  The substrate itself was found to promote viability and function of 
the embedded cells while having no deleterious impact on sensor signal.  Declines in 
sensor signal for sensors treated with macrophage-embedded gels fell within the range 
of those seen in the ex vivo studies of Chapter 4. 
In total, it may be concluded from this dissertation that instead of sensors 
“failing” in vivo, as is often reported, that different physiological factors mediate long 
term sensor function by altering the environment around the implant.  For times 
immediately following implantation, sensor signal is mediated by the presence of 
inflammatory macrophages adhered on the surface.  When only proteins and these 
inflammatory cells are present on the surface of the sensor, the inflammatory cells 
consume interstitial glucose to meet the metabolic requirements of various innate 
immune defense mechanisms.  However, at longer times post-implantation, sensor 
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signals are mediated not by the consumptive capacity of macrophages, but instead by 
the subcutaneous vessel density surrounding the sensor as well as the porosity and 
thickness of the foreign body capsule itself.  A possible explanation of this transition 
away from cell consumption as time passes is that macrophages become more 
metabolically senescent within the capsule as it matures.  Such a theory has been posed 
by Holt, et al. in in vitro studies [108]. 
As techniques for improving glucose sensing improve, so too must the 
biocompatibility of these devices in order to make implantable glucose sensors a viable 
option for diabetes management.  By outlining the major processes that negatively 
impact short and long term sensor performance in vivo, this dissertation provides the 
basis for more rational, directed and biologically-motivated sensor designs to address 
and correct for these various modes of failure.   
6.2 Future Studies 
The conclusions reported in this dissertation provide direction for future 
research by examining the link between implant-associated tissue reactions and 
implantable sensor function.  Using this work as a baseline, research into the specifics of 
innate immunity and macrophage biology as well as the consumption of oxygen, and 
not just glucose, by inflammatory cells will create a more complete profile for 
understanding implantable glucose sensor biocompatibility. 
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6.2.1 Investigating Oxygen Transport 
As oxygen is a necessary input for glucose oxidase to produce a signal, a 
thorough examination of a depleted sensing environment should also include the 
interaction between tissue and oxygen proximal to the sensor.  Inflammatory cells have 
elevated affinity for oxygen to facilitate anti-microbial defense mechanisms like 
respiratory burst.  To further complicate matters, the tissue wounded from implantation 
is shown to have decreased oxygen tension relative to untreated tissue [32-34, 109].  Such 
an increased affinity for oxygen is exacerbated by the decreased amount of oxygen 
present in wounded tissue.  Animal models have shown that 3-5 days post-injury, 
oxygen tension of the affected tissue dropped from 150 mmHg to 5-7 mmHg.  It has 
been posited that such a drop could be due to the shunting of oxygen-providing blood 
to more patent vessels away from the injured tissue [110, 111].  Gough, et al. have 
demonstrated that oxygen permeability within tissue surrounding an implant decreases 
over time, with the steepest drop coming in the first week [110].  Additionally, the 
concentration of unbound oxygen in tissue is much lower than that of glucose, meaning 
that oxygen limits the glucose oxidase reaction in the body [112, 113].  This situation of 
both increased demand and limited supply of oxygen could negatively impact sensor 
function where the sensor cannot produce hydrogen peroxide despite the presence of 
glucose.  In effect, the sensor would become more sensitive to oxygen than glucose. 
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Research from Gough, et al. has attempted to stem the potential negative impact 
of oxygen depletion by designing a different sensing regimen than that utilized by 
Medtronic [110-114].  A noticeable feature of the Medtronic sensing mechanism is that 
for every molecule of hydrogen peroxide produced, one oxygen molecule is consumed.  
In order to limit the consumption of oxygen, Gough et al. employed a two enzyme 
system [51].  Instead of reducing hydrogen peroxide like the Medtronic design, this 
design produces a glucose-dependent oxygen current from excess oxygen.  This value 
can then be subtracted from a non-enzymatic oxygen reference electrode current to give 
a glucose dependent signal.  Advantages of this design include (1) that half of the 
amount of oxygen is needed to produce a signal relative to the Medtronic design and (2) 
by producing a glucose current that is a relative measure to the ambient environment, 
the issue of decreased signal that is present in direct measurements may be avoided.  As 
Medtronic’s platform does not use this relative, oxygen based method for sensing 
glucose, it will be more susceptible to oxygen deficiencies.   
However, despite different sensing platforms, previous research has only offered 
up suggestions as to how oxygen levels could affect sensor response.  Hence, the focus 
of future studies should assess how oxygen levels, specifically hypoxic conditions, can 
alter sensor signals and well as the local environment.  If depressed oxygen levels can 
create a decrease in sensor response, there could be a synergistic effect with glucose 
consumption that creates an environment ill suited for sensing. 
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6.2.2 Investigating Macrophage Plasticity as a Potential Therapeutic 
for Improved Biocompatibility 
The hypoxic environment described previously around implants has been shown 
recently to induce expression of hypoxia inducible factor 1-alpha (HIF-1α) in 
macrophages.  This transcription factor has been shown to upregulate cell proliferation, 
as well as encourage the production of pro-inflammatory cytokines and their receptors 
that drive the cell to the M1 phenotype [115-118].  The classic phagocytic activated 
macrophage, the M1 phenotype is elicited by cytokines including interferon-gamma 
(IFN-γ) and tumor necrosis factor (TNF) as well as by Gram-negative bacterial cell wall 
lipopolysaccharides (LPS).  M1 macrophages generate large amounts of reactive oxygen 
species and inflammatory cytokines, which all serve to augment killing of phagocytosed 
intracellular parasites and local cell-mediated immune response (the Th1 response).  
While M1 macrophages are critical for the early response to injury and infection, 
prolonged or aberrant activation of M1 macrophages can also result in undesired tissue 
destruction and chronic inflammation [119]. 
The M2 macrophage phenotype describes macrophages in a broad category that 
encompasses macrophages activated in a manner different than the classic M1 
macrophages, and includes macrophages activated by IL-4, IL-13, IL-10, immune 
complexes, and glucocorticoids [119-121].  M2 macrophages promote angiogenesis, 
tissue remodeling, parasite encapsulation, and can act as immunoregulators by 
suppressing the inflammatory response.  While M2 macrophages can be activated via 
 126 
different mechanisms, they are generally characterized by low levels of IL-12 and IL-23 
secretion along with high levels of IL-10 secretion.  M1 macrophages can be 
distinguished from M2 macrophages by the expression of distinct sets of chemokines 
and chemokine receptors [121].  It has been proposed that polarization of macrophages 
towards the M2 form can create an environment that is favorable towards wound 
healing, tissue regeneration and implantable biomaterial presence [122].  Consequently, 
the identification of pathways that can be modified to regulate macrophage polarization 
will be extremely beneficial for harnessing inflammation in pathologic states.  
Stimulation of macrophages with the anti-inflammatory, pro-wound healing 
cytokine IL-10 has been shown to drive macrophages to the anti-inflammatory M2 
phenotype.  Within the realm of cancer biology, M2 phenotypes of tumor associated 
macrophages have been shown to not only be anti-inflammatory, but also pro-
angiogenic, making them potential targets in cancer therapy [115, 123-125].  Using the 
information from the previous chapters and literature that both hypoxia and cellular 
consumption of analytes negatively impact the sensing region, treatments could be 
designed to hopefully reverse these effects.  By adding therapeutic amounts of IL-10 to 
the in vitro model of sensor implantation in Chapter 5, one could show that macrophage 
phenotype can induce changes in sensor response.  Furthermore, an environment rich in 
M2 macrophages could create a more advantageous sensing environment than an M1 
environment through decreased ROS production and pro-inflammatory cytokine release 
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and increased release of pro-angiogenic factors.  As vessel density proximal to the sensor 
has been previously shown to be paramount in the long term viability of implantable 
sensors in Chapter 3, the release of these factors could encourage vessel growth at an 
earlier stage and vascularize the foreign body capsule [13, 17, 58].  This information 
could provide a valuable amount of information on future therapeutic controlled release 
mechanisms for the extended useful lives of implantable glucose sensors. 
6.2.3 Incorporation of Perfusion into the Fibrin Gel Model 
Though the gel construct designed in Chapter 5 presents an exciting new in vitro 
biomimetic surrogate for the provisional matrix surrounding an implanted sensor, it 
could be modified and improved to become more physiologically relevant.  For 
example, the construct in Chapter 5 sat in well-stirred cell media for 24 hours that was 
never replenished over the length of the experiment.  In reality though, an implanted 
sensor is bathed in interstitial fluid whose solutes are constantly being consumed and 
replenished by the flow of fluid and nutrients out of the vasculature and into the 
interstitial space.  A more accurate and physiologically relevant in vitro construct of the 
provisional matrix should incorporate this element of perfusion into the system.  A flow 
loop with inlets and outlets to the chamber containing the gel covered sensor could be 
added to provide such perfusion.  By allowing for the replenishment of nutrients to the 
gel system, this design would prevent against the depletion of nutrients in the bulk 
media phase surrounding the sensor and gel.  Additionally, a series of inlets and outlets 
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would allow for the perfusion of different therapeutics to see their effect on sensor 
function. 
6.2.4 Improving Aspects of the Computational Modeling 
The computational models presented in this dissertation described the motion of 
glucose through a porous media with respect to only one spatial direction.  While the 
assumption still allowed the models to provide very germane and useful information, a 
more complete model would incorporate more spatial components to account for spatial 
heterogeneities present in the encapsulating tissue.  Additionally, in all the simulations 
presented, the sensor was assumed to be perfectly efficient in that two electrons would 
be produced within the sensor for every glucose molecule it encounters.  While the focus 
of the research above was examining how tissue changes would alter the sensing of 
otherwise functioning sensors, terms could be incorporated to investigate how the 
biological environment could alter the efficiency by which the glucose oxidase enzyme 
converts glucose to an electrical signal.  The effects of the material properties of the 
sensors themselves could also be incorporated and help shed light on how the extent of 
injury and subsequent downstream inflammation upon implantation can be affected by 
properties such as stiffness of the sensor. 
6.2.5 Incorporating New Sensor Technology 
While the Medtronic SofSensor has been an industry standard in continuous 
glucose monitoring, the current state of the art in clinical practice is transitioning to 
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newer technologies.  With regards to Medtronic, the new state of the art design is the 
Enlite sensor design.  This design has a sensor probe that is both smaller and more 
flexible than the earlier generation SofSensor platform [126].  These design 
considerations are meant to decrease both the size of the tissue affected by the 
implantation as well as the effects of micromotion in promoting chronic inflammation.  
Moving forward, both computational models and experimental designs should be 
geared towards incorporating new sensor designs. 
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Appendix A. MATLAB Code 
A.1 Computational Model of Glucose Transport through a Fully 
Formed Capsule 
A.1.1 Main Solver Routine, glucosecapsule_solve_c.m 
function glucosecapsule_solve_c 
clear all 
global af bd bc lamb ep A D Dmac zc vm km SV P PSV kmac vmac w epmac ep_rat 
D_rat a b d b1 b2 N M dy y  
% This function is the main solver for solving for the transport of glucose 
% out of vessels and through interstitium and the foreign body capsule to 
% the surface of a glucose sensor. The program incorporates physiologically 
% relevant values, fitted blood plasma values from literature and initial 
% conditions from glucosecapsule_ic_c.m to examine the relative effects of the 
% inflammation/wound healing process on glucose transport from vasculature 
% to a sensor. 
%% Definition of model parameters %% 
tic 
af = 1;                 %sensor efficiency. assumed to be perfectly efficient. 
bd = 3.02e2;            %uM/nA. 
bc = 55.56;             %1 mg/dL = 55.56 uM. 
lamb = 2.574e-14;       %mole/(mM-sec). 
 131 
ep = 0.6;               %porosity of subcutaneous tissue. 
A = 0.0058;             %surface area of sensor probe in cm^2. 
D = 3.5e-6;            %diffusion coefficient of glucose in subcutaneous tissue. cm^2/sec. 
Dmac = (1.87e-6);         %diffusion coefficient of glucose in FBC. cm^2/sec. 
zc = 9.5e-13;           %volume of one cell. L/cell. 
vm = 3e-11;             %Vmax of glucose for Michaelis-Menten consumption by adipocytes 
in subcutaneous tissue. umol/cell/sec. 
km = 6.2e3;             %Michaelis-Menten constant of adipocytes in subcutaneous tissue. 
uM. 
SV = 15.4;              %Surface to volume ratio of blood vessels. cm^-1. 
P = 5e-5;               %Permeability constant for glucose through blood vessels in cm/sec. 
PSV = P*SV;             %Product of permeability and surface to volume ratio. 1/sec. 
kmac = 6.13e3;          %Michaelis-Menten constant of macrophages in FBC. uM. 
vmac = (4.88e-11);        %Vmax of glucose for Michaelis-Menten consumption by 
macrophages in FBC. umol/cell/sec. 
w = 0.0075;             %Width of fibrous capsule layer in cm. 
epmac = 0.6;            %Porosity of FBC. unitless. 
ep_rat = ep/epmac;      %Ratio of subcutaneous porosity divided by FBC porosity. no 
units. 
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D_rat = D/Dmac;         %Ratio of subcutaneous diffusion coefficient divided by FBC 
diffusion coefficient. no units. 
%==Blood Plasma Concentration for Initial Condition Vector==% 
a=[]; 
b=[]; 
d=[]; 
%\\\\\\\\\from data from gough paper\\\\\\\\\\\\\\% 
%\\\\\\data fit to sum of three gaussians\\\\\\% 
%\\ Cp=a(1)*exp(-((t-b(1))/d(1)).^2) + a(2)*exp(-((t-b(2))/d(2)).^2)+a(3)*exp(-((t-
b(3))/d(3)).^2)\\% 
a(1)=43.28;           %mg/dL 
a(2)=102.2;           %mg/dL 
a(3)=1.214e7;         %mg/dL 
b(1)=41.38*60;        %sec 
b(2)=65.9*60;         %sec 
b(3)=5.021e4*60;      %sec 
d(1)=12.23*60;        %sec 
d(2)=21.73*60;        %sec 
d(3)=1.427e4*60;      %sec 
%% Mesh definition and solution of PDEs %% 
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b1 = 5.07;             %cm. Let y=b1(1-exp(-b2*x)) to make a nonlinearly spaced mesh to 
better define behavior at short times.  
M = 500;               %Number of spatial iterations in FBC layer.  
N = 1000;              %Number of spatial iterations in subcutaneous layer. 
yo=0.07; 
y=linspace(yo,b1,N+1); 
dy=y(2)-y(1); 
b2 = (-1./(w)).*(log((b1-y(M))./b1));   %1/cm. equations for dc/dx will be analytically 
transformed to make dc/dy. 
t0 = 0; 
tend = 10000; 
t_interval = linspace(t0,tend,4000);    %Timespan of simulation in sec. 
Cp = bc.*(a(1).*exp(-((t_interval-b(1))/d(1)).^2) + a(2).*exp(-((t_interval-b(2))/d(2)).^2) + 
a(3).*exp(-((t_interval-b(3))/d(3)).^2));  %Blood glucose profile. 
Co = [glucosecapsule_ic_c]; %Calls the initial condition vector from subroutine 
glucosecapsule_ic_c.m. This routine is outlined below. 
sol_init = Co(1:N);  %Initial condition vector. Baseline value in subcutaneous tissue layer. 
[tnum,sol] = ode15s(@func, t_interval,sol_init);      %Solution of PDEs as a system of 
ODEs. 
%Making concentration matrix from solution matrix% 
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con_mat = [sol(:,(1:M)) ep_rat.*sol(:,M) sol(:,(M+1:N-1)) ep.*Cp']; %Pieces together the 
FBC compartment, interface, native tissue and outer BC into solution matrix. 
%Calculating time lag 
xcp = find(ep.*Cp==max(ep.*Cp)); %Finds the index of the max value in the time trace at 
the last point in the simulation. 
tcp = t_interval(xcp)/60; %Uses the above index to find the time at which the peak value 
of the time trace at the last point in the simulation occurs. 
xg = find(con_mat(:,1)==max(con_mat(:,1))); %Finds the index of the max value in the 
time trace at the first point in the simulation (at the sensor surface). 
tg = t_interval(xg)/60; %Uses the above index to find the time at which the peak value of 
the time trace at the first point in the simulation occurs. 
lag = tg - tcp %Calculates lag as the difference between the times calculated above. 
%Calculating the attenuation 
atten = 1-con_mat(xg,1)./(ep.*Cp(xcp)) %Calculates attenuation as the quotient of the 
peak sensor value divided by the peak value in the tissue. 
%% Plotting solutions %% 
%Plot trace of concentration at sensor surface versus at last point in 
%simulation. 
figure(1)  
hold on 
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plot(t_interval/60,con_mat(:,1),'k--','LineWidth',2) %Sensor surface model results. 
plot(t_interval/60,ep.*Cp,'k','LineWidth',2)         %Last point in simulation. 
xlabel('Time (min)','fontsize',10) 
ylabel('Glucose Concentration (\muM)','fontsize',10) 
set(gca,'fontsize',10) 
legend('C_{surface}(t)','\epsilonC_{p}(t)') 
box on 
toc 
%% ODE-writing subroutine %% 
function dcdt = func(t,c) 
global af bd bc lamb ep A D Dmac zc vm km SV P PSV kmac vmac w epmac ep_rat 
D_rat a b d b1 b2 N M dy y Cp 
dcdt = []; 
%=FBC equations=% 
Cp = bc.*(a(1).*exp(-((t-b(1))/d(1)).^2) + a(2).*exp(-((t-b(2))/d(2)).^2)+ a(3).*exp(-((t-
b(3))/d(3)).^2)); 
%at y=0% 
Qsensor = af.*lamb.*c(1)./epmac; 
dcdy_o = Qsensor./(Dmac.*A.*(b1-y(1))*b2); 
dcdy2_o=(2.*(c(2)-c(1)-dcdy_o.*dy))/(dy.*dy); 
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%Between y=0 and y=L 
dcdt(1)=Dmac.*b2.*b2.*((y(1)-b1).^2).*dcdy2_o + Dmac.*b2.*b2.*(y(1)-b1).*(1+1./(log((b1-
y(1))./b1))).*dcdy_o-((vmac.*c(1))./(kmac.*epmac+c(1)).*((1-epmac)./zc)); 
for k=2:M-1 
    dcdt(k)=Dmac.*b2.*b2.*((y(k)-b1).^2).*((c(k+1)-2.*c(k)+c(k-1))./(dy.*dy)) + 
Dmac.*b2.*b2.*(y(k)-b1).*(1+1./(log((b1-y(k))./b1))).*(c(k+1)-c(k))./dy-
((vmac.*c(k))./(kmac.*epmac+c(k)).*((1-epmac)./zc)); 
end 
dcdy2_L = (2.*(c(M-1)-c(M)+D_rat.*(c(M+1)-ep_rat.*c(M))))./(dy.*dy); 
dcdt(M) = Dmac.*b2.*b2.*((y(M)-b1).^2).*dcdy2_L + Dmac.*(1+1./(log((b1-
y(M))./b1))).*(b2.^2).*((y(M)-b1)).*D_rat.*((c(M+2)-ep_rat.*c(M))./dy)- 
((vmac.*c(M))./(kmac.*epmac+c(M)).*((1-epmac)./zc)); 
%for L<y<N% 
%right side of y=L% 
c2_1 = ep_rat.*c(M); 
%second point of second compartment% 
dcdt(M+1) = D.*b2.*b2.*((y(M+2)-b1).^2).*((c(M+2)-2.*c(M+1)+c2_1)./(dy.*dy)) + 
D.*b2.*b2.*(y(M+2)-b1).*((c(M+2)-c(M+1))./dy).*(1+1./(log((b1-y(M+2))./b1)))- 
((vm.*c(M+1))./(km.*ep+c(M+1)).*((1-ep)./zc)) + PSV.*(Cp-c(M+1)./ep); 
for k=M+2:N-2 
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    dcdt(k) = D.*b2.*b2.*((y(k+1)-b1).^2).*((c(k+1)-2*c(k)+c(k-1))./(dy*dy)) + 
D.*b2.*b2.*(y(k+1)-b1).*((c(k+1)-c(k))./dy).*(1+1./(log((b1-y(M))./b1)))-
((vm.*c(k))./(km.*ep+c(k)).*((1-ep)./zc)) + PSV.*(Cp-c(k)./ep); 
end 
%for y=N% 
dcdy_N = (ep.*Cp-c(N-1))./dy; 
dcdy2_N = (ep.*Cp-2*c(N-1)+c(N-2))./(dy*dy); 
dcdt(N) = D.*b2.*b2.*((y(N)-b1).^2).*dcdy2_N + D.*b2.*b2.*((y(N)-
b1)).*(dcdy_N).*(1+1./(log((b1-y(N))./b1)))- (vm.*c(N-1))/(km*ep+c(N-1)).*((1-ep)./zc) + 
PSV.*(Cp-c(N-1)./ep); 
dcdt=dcdt'; 
A.1.2 Initial Condition Solver, glucosecapsule_ic_c.m 
function [ss_trace]= glucosecapsule_ic_c 
global af bd bc lamb ep A D Dmac zc vm km SV P PSV kmac vmac w epmac ep_rat 
D_rat a b d b1 b2 N M dy y Cp_exp 
  
% This program is used to find the initial condition for the main solver 
% program, glucosecapsule_solve_ic.m. The simulation is run with initial 
% conditions set to zero in the FBC layer and a baseline value from 
% literature in the subcutaneous tissue to see at what point the system 
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% reaches steady state. This is because the FBC is assumed to have no 
% vessels and vessels are the only source of glucose considered. The trace 
% of concentration as a function of position at that point in time is then 
% exported to the main solver to be used as the initial condition vector as 
% the vector "ss_trace". It is thought that this vector is representative 
% of the standard glucose trace in the tissue before a glucose challenge. 
  
%==Definition of model parameters==% 
tic 
af = 1;                 %sensor efficiency. assumed to be perfectly efficient. 
bd = 3.02e2;            %uM/nA. 
bc = 55.56;             %1 mg/dL = 55.56 uM. 
lamb = 2.574e-14;       %mole/(mM-sec). 
ep = 0.6;               %porosity of subcutaneous tissue. unitless 
A = 0.0058;             %surface area of sensor probe in cm^2. 
D = 3.5e-6;            %diffusion coefficient of glucose in subcutaneous tissue. cm^2/sec. 
Dmac = (1.87e-6);        %diffusion coefficient of glucose in FBC. cm^2/sec. 
zc = 9.5e-13;           %volume of one cell. L/cell. 
vm = 3e-11;             %Vmax of glucose for Michaelis-Menten consumption by adipocytes 
in subcutaneous tissue. umol/cell/sec. 
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km = 6.2e3;             %Michaelis-Menten constant of adipocytes in subcutaneous tissue. 
uM. 
SV = 15.4;              %Surface to volume ratio of blood vessels. cm^-1. 
P = 5e-5;               %Permeability constant for glucose through blood vessels in cm/sec. 
PSV = P*SV;             %Product of permeability and surface to volume ratio. 1/sec. 
kmac = 6.13e3;          %Michaelis-Menten constant of macrophages in FBC. uM. 
vmac = (4.88e-11);      %Vmax of glucose for Michaelis-Menten consumption by 
macrophages in FBC. umol/cell/sec. 
w = 0.0075;             %Width of fibrous capsule layer in cm. 
epmac = 0.6;            %porosity of FBC. unitless. 
ep_rat = ep/epmac;      %Ratio of subcutaneous porosity divided by FBC porosity. no 
units. 
D_rat = D/Dmac;         %Ratio of subcutaneous diffusion coefficient divided by FBC 
diffusion coefficient. no units. 
%==Blood Plasma Concentration for Initial Condition Vector==% 
a=[]; 
b=[]; 
d=[]; 
%\\\\\\\\\from data from gough paper\\\\\\\\\\\\\\% 
%\\\\\\data fit to sum of three gaussians\\\\\\% 
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%\\ Cp=a(1)*exp(-((t-b(1))/d(1)).^2) + a(2)*exp(-((t-b(2))/d(2)).^2)+a(3)*exp(-((t-
b(3))/d(3)).^2)\\% 
a(1)=43.28;           %mg/dL 
a(2)=102.2;           %mg/dL 
a(3)=1.214e7;         %mg/dL 
b(1)=41.38*60;        %sec 
b(2)=65.9*60;         %sec 
b(3)=5.021e4*60;      %sec 
d(1)=12.23*60;        %sec 
d(2)=21.73*60;        %sec 
d(3)=1.427e4*60;      %sec 
 %==Mesh definition and solution of PDEs==% 
b1 = 5.07;                %cm. Let y=b1(1-exp(-b2*x)) to make a nonlinearly spaced mesh to 
better define behavior at short times.  
M = 500;               %Number of spatial iterations in FBC layer.  
N = 1000;              %Number of spatial iterations in subcutaneous layer. 
yo=0.07; 
y=linspace(yo,b1,N+1); 
dy=y(2)-y(1); 
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b2 = (-1./(w)).*(log((b1-y(M))./b1));   %1/cm. equations for dc/dx will be analytically 
transformed to make dc/dy. 
t0 = 0; 
tend = 10000; 
t_interval = linspace(t0,tend,5000);    %Timespan of simulation in sec. 
dt = t_interval(2)-t_interval(1); 
Cp_exp=a(1)*exp(-((t0-b(1))/d(1)).^2) + a(2)*exp(-((t0-b(2))/d(2)).^2)+a(3)*exp(-((t0-
b(3))/d(3)).^2);  %baseline value of glucose in vessels before bolus injection. Based on 
Gough. 
sol_init = [zeros(1,M) ep.*bc.*Cp_exp.*ones(1,N-M)];  %Initial condition vector. Zero in 
FBC layer because no source. Baseline value in subcutaneous tissue layer 
[tnum,sol] = ode15s(@func, t_interval,sol_init);      %Solution of PDEs as a system of 
ODEs 
%making concentration matrix from solution matrix% 
con_mat = [sol(:,(1:M)) ep_rat.*sol(:,M) sol(:,(M+1:N-1)) 
ep.*bc.*Cp_exp.*ones(length(t_interval),1)]; 
%==ODE-writing subroutine==% 
function dcdt = func(t,c) 
global af bd bc lamb ep A D Dmac zc vm km SV P PSV kmac vmac w epmac ep_rat 
D_rat a b d b1 b2 N M dy y Cp_exp 
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dcdt = []; 
 %=FBC equations=% 
Cp = bc.*Cp_exp; 
%at y=0% 
Qsensor = af.*lamb.*c(1)./epmac; 
dcdy_o = Qsensor./(Dmac.*A.*(b1-y(1))*b2); 
dcdy2_o=(2.*(c(2)-c(1)-dcdy_o.*dy))/(dy.*dy); 
dcdt(1)=Dmac.*b2.*b2.*((y(1)-b1).^2).*dcdy2_o + Dmac.*b2.*b2.*(y(1)-b1).*(1+1./(log((b1-
y(1))./b1))).*dcdy_o-((vmac.*c(1))./(kmac.*epmac+c(1)).*((1-epmac)./zc)); 
for k=2:M-1 
    dcdt(k)=Dmac.*b2.*b2.*((y(k)-b1).^2).*((c(k+1)-2.*c(k)+c(k-1))./(dy.*dy)) + 
Dmac.*b2.*b2.*(y(k)-b1).*(1+1./(log((b1-y(k))./b1))).*(c(k+1)-c(k))./dy-
((vmac.*c(k))./(kmac.*epmac+c(k)).*((1-epmac)./zc)); 
end 
dcdy2_L = (2.*(c(M-1)-c(M)+D_rat.*(c(M+1)-ep_rat.*c(M))))./(dy.*dy); 
dcdt(M) = Dmac.*b2.*b2.*((y(M)-b1).^2).*dcdy2_L + Dmac.*(1+1./(log((b1-
y(M))./b1))).*(b2.^2).*((y(M)-b1)).*D_rat.*((c(M+2)-ep_rat.*c(M))./dy)- 
((vmac.*c(M))./(kmac.*epmac+c(M)).*((1-epmac)./zc)); 
%for L<y<N% 
%right side of y=L% 
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c2_1 = ep_rat.*c(M); 
%second point of second compartment% 
dcdt(M+1) = D.*b2.*b2.*((y(M+2)-b1).^2).*((c(M+2)-2.*c(M+1)+c2_1)./(dy.*dy)) + 
D.*b2.*b2.*(y(M+2)-b1).*((c(M+2)-c(M+1))./dy).*(1+1./(log((b1-y(M+2))./b1)))- 
((vm.*c(M+1))./(km.*ep+c(M+1)).*((1-ep)./zc)) + PSV.*(Cp-c(M+1)./ep); 
for k=M+2:N-2 
    dcdt(k) = D.*b2.*b2.*((y(k+1)-b1).^2).*((c(k+1)-2*c(k)+c(k-1))./(dy*dy)) + 
D.*b2.*b2.*(y(k+1)-b1).*((c(k+1)-c(k))./dy).*(1+1./(log((b1-y(M))./b1)))-
((vm.*c(k))./(km.*ep+c(k)).*((1-ep)./zc)) + PSV.*(Cp-c(k)./ep); 
end 
%for y=N% 
dcdy_N = (ep.*Cp-c(N-1))./dy; 
dcdy2_N = (ep.*Cp-2*c(N-1)+c(N-2))./(dy*dy); 
dcdt(N) = D.*b2.*b2.*((y(N)-b1).^2).*dcdy2_N + D.*b2.*b2.*((y(N)-
b1)).*(dcdy_N).*(1+1./(log((b1-y(N))./b1)))- (vm.*c(N-1))/(km*ep+c(N-1)).*((1-ep)./zc) + 
PSV.*(Cp-c(N-1)./ep); 
dcdt=dcdt'; 
A.2. Computational Model of Transport through the Provisional 
Matrix in a Whole Blood Solution, glucosecapsule_noflux.m 
function glucosecapsule_ic_time_noflux 
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global af bd bc lamb ep A D Dmac zc vm km SV P PSV kmac vmac w epmac ep_rat 
D_rat a b d b1 b2 N M dy y Cp_exp 
  
% This program is used to find the normalized concentration of glucose with 
% respect to time at the sensor surface. 
  
%==Definition of model parameters==% 
tic 
af = 1;                 %sensor efficiency. assumed to be perfectly efficient. 
bd = 3.02e2;            %uM/nA. 
bc = 55.56;             %1 mg/dL = 55.56 uM. 
lamb = 2.574e-14;       %mole/(mM-sec). 
ep = 0.55;               %porosity of bulk blood. unitless 
A = 0.0058;             %surface area of sensor probe in cm^2. 
D = 3.5e-6;            %diffusion coefficient of glucose in bulk blood. cm^2/sec. 
Dmac = (1.87e-6);        %diffusion coefficient of glucose in provisional matrix. cm^2/sec. 
zc = 9.5e-13;           %volume of one cell. L/cell. 
vm = 1.357e-12;             %Vmax of glucose for Michaelis-Menten consumption by 
erythrocytes. umol/cell/sec. 
km = 6.2e3;             %Michaelis-Menten constant of erythrocytes uM. 
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kmac = 6.13e3;          %Michaelis-Menten constant of macrophages in FBC. uM. 
vmac = 4.88e-11;      %Vmax of glucose for Michaelis-Menten consumption by 
macrophages. umol/cell/sec. 
w = 0.0075;             %Width of provisional matrix layer in cm. 
epmac = 0.91;            %porosity of provisional matrix. unitless. 
ep_rat = ep/epmac;      %Ratio of subcutaneous porosity divided by FBC porosity. no 
units. 
D_rat = D/Dmac;         %Ratio of subcutaneous diffusion coefficient divided by FBC 
diffusion coefficient. no units. 
%==Mesh definition and solution of PDEs==% 
b1 = 1.25;                %cm. Let y=b1(1-exp(-b2*x)) to make a nonlinearly spaced mesh to 
better define behavior at short times.  
M = 500;               %Number of spatial iterations in FBC layer.  
N = 1000;              %Number of spatial iterations in subcutaneous layer. 
yo=0.07; 
y=linspace(yo,b1,N+1); 
dy=y(2)-y(1); 
b2 = (-1./(w)).*(log((b1-y(M))./b1))   %1/cm. equations for dc/dx will be analytically 
transformed to make dc/dy. 
 t0 = 0; 
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tend = 86400; 
t_interval = linspace(t0,tend,5000);    %Timespan of simulation in sec. 
dt = t_interval(2)-t_interval(1); 
Cp_exp= 55./ep;  %baseline value of glucose in vessels before bolus injection. Based on 
Gough. 
sol_init = [bc.*Cp_exp.*ones(1,N)]; 
[tnum,sol] = ode15s(@func, t_interval,sol_init);      %Solution of PDEs as a system of 
ODEs 
%making concentration matrix from solution matrix% 
con_mat = [sol(:,(1:M)) ep_rat.*sol(:,M) sol(:,(M+1:N))]; 
%==Plotting solutions==% 
plot(t_interval((1:end))./3600,con_mat((1:end),1)./con_mat(1,1),'k--','LineWidth',2) 
%==ODE-writing subroutine==% 
function dcdt = func(t,c) 
global af bd bc lamb ep A D Dmac zc vm km SV P PSV kmac vmac w epmac ep_rat 
D_rat a b d b1 b2 N M dy y Cp_exp 
dcdt = []; 
 %=FBC equations=% 
Cp = bc.*Cp_exp; 
%at y=0% 
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Qsensor = af.*lamb.*c(1)./epmac; 
dcdy_o = Qsensor./(Dmac.*A.*(b1-y(1))*b2); 
dcdy2_o=(2.*(c(2)-c(1)-dcdy_o.*dy))/(dy.*dy); 
dcdt(1)=Dmac.*b2.*b2.*((y(1)-b1).^2).*dcdy2_o + Dmac.*b2.*b2.*(y(1)-b1).*(1+1./(log((b1-
y(1))./b1))).*dcdy_o-((vmac.*c(1))./(kmac.*epmac+c(1)).*((1-epmac)./zc)); 
for k=2:M-1 
    dcdt(k)=Dmac.*b2.*b2.*((y(k)-b1).^2).*((c(k+1)-2.*c(k)+c(k-1))./(dy.*dy)) + 
Dmac.*b2.*b2.*(y(k)-b1).*(1+1./(log((b1-y(k))./b1))).*(c(k+1)-c(k))./dy-
((vmac.*c(k))./(kmac.*epmac+c(k)).*((1-epmac)./zc)); 
end 
dcdy2_L = (2.*(c(M-1)-c(M)+D_rat.*(c(M+1)-ep_rat.*c(M))))./(dy.*dy); 
dcdt(M) = Dmac.*b2.*b2.*((y(M)-b1).^2).*dcdy2_L + Dmac.*(1+1./(log((b1-
y(M))./b1))).*(b2.^2).*((y(M)-b1)).*D_rat.*((c(M+2)-ep_rat.*c(M))./dy)- 
((vmac.*c(M))./(kmac.*epmac+c(M)).*((1-epmac)./zc)); 
%for L<y<N% 
%right side of y=L% 
c2_1 = ep_rat.*c(M); 
%second point of second compartment% 
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dcdt(M+1) = D.*b2.*b2.*((y(M+1)-b1).^2).*((c(M+2)-2.*c(M+1)+c2_1)./(dy.*dy)) + 
D.*b2.*b2.*(y(M+1)-b1).*((c(M+2)-c(M+1))./dy).*(1+1./(log((b1-y(M+1))./b1)))- 
((vm.*c(M+1))./(km.*ep+c(M+1)).*((1-ep)./zc)); 
for k=M+2:N-1 
    dcdt(k) = D.*b2.*b2.*((y(k)-b1).^2).*((c(k+1)-2*c(k)+c(k-1))./(dy*dy)) + D.*b2.*b2.*(y(k)-
b1).*((c(k+1)-c(k))./dy).*(1+1./(log((b1-y(k))./b1)))-((vm.*c(k))./(km.*ep+c(k)).*((1-ep)./zc)); 
end 
%for y=N% 
dcdy_N = 0; %because no flux boundary condition 
dcdy2_N = (2.*(c(N-1)-c(N)))./(dy*dy); 
dcdt(N) = D.*b2.*b2.*((y(N)-b1).^2).*dcdy2_N - (vm.*c(N))/(km*ep+c(N)).*((1-ep)./zc); 
dcdt=dcdt'; 
 
A.3 Computational Model of Glucose Flux through Fibrin Gel, 
glucosegel_noflux_vmac.m 
function [con_mat] = glucosegel_noflux_vmac(vmac) 
clear all 
global af bd bc lamb ep A D Dmac zc vm km SV P PSV kmac vmac w epmac ep_rat 
D_rat a b d b1 b2 N M dy y Cp_exp epgel 
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% This program is used to the find the normalized concentration of glucose  on the 
sensor surface with respect to time for a varying number of values of Vmax in the gel. 
These values will then be compared to experimental traces in model_compare.m. 
  
%==Definition of model parameters==% 
tic 
af = 1;                 %sensor efficiency. assumed to be perfectly efficient. 
bd = 3.02e2;            %uM/nA. 
bc = 55.56;             %1 mg/dL = 55.56 uM. 
lamb = 2.574e-14;       %mole/(mM-sec). 
ep = 1;               %porosity of bulk fluid. unitless 
A = 0.0058;             %surface area of sensor probe in cm^2. 
D = 6.8e-6;            %diffusion coefficient of glucose in fluid. cm^2/sec. 
Dmac = 6.8e-6;        %diffusion coefficient of glucose in gel. cm^2/sec. 
zc = 2.1e-12;           %volume of one cell. L/cell. 
kmac = [6.13e3];          %Michaelis-Menten constant of macrophages in gel. uM. 
% vmac = [input from the function line];     Vmax of glucose for Michaelis-Menten 
consumption by macrophages in FBC. umol/cell/sec. 
w = 0.43;             %Width of gel in cm. 
epmac = 1-0.0257;            %fraction of gel that is cells. unitless. 
 150 
ep_rat = ep/epmac;      %Ratio of fluid porosity divided by gel porosity. no units. 
D_rat = D/Dmac;         %Ratio of fluid diffusion coefficient divided by gel diffusion 
coefficient. no units. 
%==Mesh definition and solution of PDEs==% 
b1 = 1.1;                %cm. Let y=b1(1-exp(-b2*x)) to make a nonlinearly spaced mesh to 
better define behavior at short times.  
M = 250;               %Number of spatial iterations in gel layer.  
N = 500;              %Number of spatial iterations in media layer. 
yo=0.07; 
y=linspace(yo,b1,N+1); 
dy=y(2)-y(1); 
b2 = (-1./(w)).*(log((b1-y(M))./b1));   %1/cm. equations for dc/dx will be analytically 
transformed to make dc/dy. 
  
t0 = 0; 
tend = 7200; 
t_interval = linspace(t0,tend,1000);    %Timespan of simulation in sec. 
dt = t_interval(2)-t_interval(1); 
Cp_exp= 100;  %baseline value of glucose 
sol_init = [bc.*Cp_exp.*ones(1,length(vmac)*N)]; 
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[tnum,sol] = ode15s(@func, t_interval,sol_init);      %Solution of PDEs as a system of 
ODEs 
%=Making concentration matrix from solution matrix=% 
con_mat=[]; 
con_mat(:,(1:N+1)) = [sol(:,(1:M)) ep_rat.*sol(:,M) sol(:,(M+1:N))]; 
for i=1:length(vmac)-1 
    con_mat(:,(i*N+i+1:(i+1).*N+i+1)) = [sol(:,(i.*N+1:i*N+M)) ep_rat.*sol(:,i*N+M) 
sol(:,(i*N+M+1:(i+1)*N))]; 
end 
 % %==Plotting solutions==% 
hold all 
for i=1:length(vmac)-1 
    plot(t_interval./3600,con_mat(:,1)./bc./Cp_exp,'--','LineWidth',2) 
    plot(t_interval./3600,con_mat(:,i*N+i+1)./bc./Cp_exp,'--','LineWidth',2) 
    box on 
end 
toc 
%==ODE-writing subroutine==% 
function dcdt = func(t,c) 
 152 
global af bd bc lamb ep A D Dmac zc vm km SV P PSV kmac vmac w epmac ep_rat 
D_rat a b d b1 b2 N M dy y Cp_exp epgel 
dcdt = []; 
  
%=FBC equations=% 
Cp = bc.*Cp_exp; 
%at y=0% 
Qsensor = af.*lamb.*c(1)./epmac; 
dcdy_o = Qsensor./(Dmac.*A.*(b1-y(1))*b2); 
dcdy2_o=(2.*(c(2)-c(1)-dcdy_o.*dy))/(dy.*dy); 
dcdt(1)=Dmac.*b2.*b2.*((y(1)-b1).^2).*dcdy2_o + Dmac.*b2.*b2.*(y(1)-b1).*(1+1./(log((b1-
y(1))./b1))).*dcdy_o-((vmac(1).*c(1))./(kmac.*epmac+c(1)).*((1-epmac)./zc)); 
for k=2:M-1 
    dcdt(k)=Dmac.*b2.*b2.*((y(k)-b1).^2).*((c(k+1)-2.*c(k)+c(k-1))./(dy.*dy)) + 
Dmac.*b2.*b2.*(y(k)-b1).*(1+1./(log((b1-y(k))./b1))).*(c(k+1)-c(k))./dy-
((vmac(1).*c(k))./(kmac.*epmac+c(k)).*((1-epmac)./zc)); 
end 
dcdy2_L = (2.*(c(M-1)-c(M)+D_rat.*(c(M+1)-ep_rat.*c(M))))./(dy.*dy); 
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dcdt(M) = Dmac.*b2.*b2.*((y(M)-b1).^2).*dcdy2_L + Dmac.*(1+1./(log((b1-
y(M))./b1))).*(b2.^2).*((y(M)-b1)).*D_rat.*((c(M+2)-ep_rat.*c(M))./dy)- 
((vmac(1).*c(M))./(kmac.*epmac+c(M)).*((1-epmac)./zc)); 
%for L<y<N% 
%right side of y=L% 
c2_1 = ep_rat.*c(M); 
%second point of second compartment% 
dcdt(M+1) = D.*b2.*b2.*((y(M+1)-b1).^2).*((c(M+2)-2.*c(M+1)+c2_1)./(dy.*dy)) + 
D.*b2.*b2.*(y(M+1)-b1).*((c(M+2)-c(M+1))./dy).*(1+1./(log((b1-y(M+1))./b1)))- 
((vm.*c(M+1))./(km.*ep+c(M+1)).*((1-ep)./zc)); 
for k=M+2:N-1 
    dcdt(k) = D.*b2.*b2.*((y(k)-b1).^2).*((c(k+1)-2*c(k)+c(k-1))./(dy*dy)) + D.*b2.*b2.*(y(k)-
b1).*((c(k+1)-c(k))./dy).*(1+1./(log((b1-y(k))./b1)))-((vm.*c(k))./(km.*ep+c(k)).*((1-ep)./zc)); 
end 
%for y=N% 
dcdy_N = 0; %because no flux boundary condition 
dcdy2_N = (2.*(c(N-1)-c(N)))./(dy*dy); 
dcdt(N) = D.*b2.*b2.*((y(N)-b1).^2).*dcdy2_N - (vm.*c(N))/(km*ep+c(N)).*((1-ep)./zc); 
%=for the other values of vmac=% 
for i=1:length(vmac)-1 
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    Qsensor1 = af.*lamb.*c(i*N+1)./epmac; 
    dcdy_o1 = Qsensor1./(Dmac.*A.*(b1-y(1))*b2); 
    dcdy2_o1=(2.*(c(i.*N+2)-c(i.*N+1)-dcdy_o1.*dy))/(dy.*dy); 
    dcdt(i.*N+1)=Dmac.*b2.*b2.*((y(1)-b1).^2).*dcdy2_o1 + Dmac.*b2.*b2.*(y(1)-
b1).*(1+1./(log((b1-y(1))./b1))).*dcdy_o1-
((vmac(i+1).*c(i*N+1))./(kmac.*epmac+c(i*N+1)).*((1-epmac)./zc)); 
    for k=2:M-1 
        dcdt(i.*N+k)=Dmac.*b2.*b2.*((y(k)-b1).^2).*((c(i.*N+k+1)-2.*c(i.*N+k)+c(i.*N+k-
1))./(dy.*dy)) + Dmac.*b2.*b2.*(y(k)-b1).*(1+1./(log((b1-y(k))./b1))).*(c(i.*N+k+1)-
c(i.*N+k))./dy-((vmac(i+1).*c(i.*N+k))./(kmac.*epmac+c(i.*N+k)).*((1-epmac)./zc)); 
    end 
    dcdy2_L = (2.*(c(i.*N+M-1)-c(i.*N+M)+D_rat.*(c(i.*N+M+1)-
ep_rat.*c(i.*N+M))))./(dy.*dy); 
    dcdt(i.*N+M) = Dmac.*b2.*b2.*((y(M)-b1).^2).*dcdy2_L + Dmac.*(1+1./(log((b1-
y(M))./b1))).*(b2.^2).*((y(M)-b1)).*D_rat.*((c(i.*N+M+2)-ep_rat.*c(i.*N+M))./dy)- 
((vmac(i+1).*c(i.*N+M))./(kmac.*epmac+c(i.*N+M)).*((1-epmac)./zc)); 
    c2_1 = ep_rat.*c(i.*N+M); 
    %second point of second compartment% 
    dcdt(i.*N+M+1) = D.*b2.*b2.*((y(M+1)-b1).^2).*((c(i.*N+M+2)-
2.*c(i.*N+M+1)+c2_1)./(dy.*dy)) + D.*b2.*b2.*(y(M+1)-b1).*((c(i.*N+M+2)-
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c(i.*N+M+1))./dy).*(1+1./(log((b1-y(M+1))./b1)))- 
((vm.*c(i.*N+M+1))./(km.*ep+c(i.*N+M+1)).*((1-ep)./zc)); 
    for k=M+2:N-1 
        dcdt(i.*N+k) = D.*b2.*b2.*((y(k)-b1).^2).*((c(i.*N+k+1)-2*c(i.*N+k)+c(i.*N+k-
1))./(dy*dy)) + D.*b2.*b2.*(y(k)-b1).*((c(i.*N+k+1)-c(i.*N+k))./dy).*(1+1./(log((b1-
y(k))./b1)))-((vm.*c(i.*N+k))./(km.*ep+c(i.*N+k)).*((1-ep)./zc)); 
    end 
    dcdy_N = 0; %because no flux boundary condition 
    dcdy2_N = (2.*(c((i+1).*N-1)-c((i+1).*N)))./(dy*dy); 
    dcdt((i+1).*N) = D.*b2.*b2.*((y(N)-b1).^2).*dcdy2_N - 
(vm.*c((i+1).*N))/(km*ep+c((i+1).*N)).*((1-ep)./zc); 
end 
dcdt=dcdt'; 
A.4 Algorithm for Finding Best Fit of Experimental Data from 
glucosegel_noflux_vmac, model_compare.m 
%model_compare.m 
 
%This program compares modeled normalized sensor traces to experimentally 
%observed traces by calculating the R^2 values between experimental and modeled 
cases.  Those fits with the highest R^2 values to experimental traces are considered to be 
best fits. 
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s=openfig('MeanMacValues_with_error_gen.fig'); %Loads the experimental traces 
h=findobj(s,'type','line'); 
x=get(h,'xdata'); 
y=get(h,'ydata'); 
 
mac=cell2mat(y(2,1)); %Turns experimental sensor trace into numerical vector from a 
cell 
pma=cell2mat(y(3,1)); 
lps=cell2mat(y(4,1)); 
 
model_trace=glucosegel_noflux_vmac; %Load modeled results 
N=500; %Number of spatial iterations in modeled results 
for i=1:length(vmac)-1 
    sensor_model=[model_trace(:,1) con_mat(:,i*N+i+1)]; 
end 
%Calculate the total sum of squares for each case 
sst_mac = sum((mac-mean(mac)).^2); 
sst_pma = sum((pma-mean(pma)).^2); 
sst_lps = sum((lps-mean(lps)).^2); 
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%Calculate the residual sum of squares for each case 
for i=1:size(sensor_model,2) 
        ssr_mac(:,i) = sum((mac-sensor_model(:,i)).^2); 
        ssr_pma(:,i) = sum((pma-sensor_model(:,i)).^2); 
        ssr_lps(:,i) = sum((lps-sensor_model(:,i)).^2); 
end 
%Calculate the R^2 value for each case 
for i=1:size(sensor_model,2) 
        r2_mac(:,i) = 1-ssr_mac(:,i)./sst_mac; 
        r2_pma(:,i) = 1-ssr_pma(:,i)./sst_pma; 
        r2_lps(:,i) = 1-ssr_lps(:,i)./sst_lps; 
end 
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